,ticker,content
0,HOLX,idexx laboratory idxx cater niche clientele keep push back launch next product trade multiple time earning xto investor sound big thank yet wall street pro laud veterinary diagnostic company management brilliant unbelievable grasp business simply put company execution continue be second none raymond james analyst john ransom say recent note client ransom go say further be not often player space dominant approximately market share be able maintain base highly competitive market yet idexx post placement number suggest even be gain share get newsletter deliver inbox more info product service privacy policy term thing niche market question be veterinary market sound small number be fewer veterinarian animal health clinic accord census bureau annually vet serve million very passionate customer pet owner well pet household have pet accord american pet product association translate nearly dog more cat not mention multitude bird fish other creature hang person home most recent annual survey reveal dog owner spend annual average routine surgical vet visit combine cat owner shell idexx be industry leader supply vet technology run clinic test blood work cater primarily beloved canine feline abroad raymond james ransom canaccord genuity analyst mark massaro peg company stateside market share hefty player abaxis abax have corner quarter american market smaller competitor heska hska have tenth vca unit antech diagnostic zoetis zts latter be acquire abaxis also number rival water treatment livestock product account sliver idexx revenue big money come companion animal diagnostic business include suite clinic product such chemistry panel rapid test kit veterinary instrument analyzer be also external laboratory service such diagnostic imaging testing companion animal diagnostic unit bring idexx more net revenue overall haul year person simply take pet vet be likely result idexx test equipment be used kind diagnostic test be administer time person bring fluffy friend clinic idexx say investor day presentation last august pet owner tend not object fact millennial pet owner be more likely older peer say money be object come pet accord idexx survey work percent year old feel way vs gen xer baby boomer younger person get laser focuse career longer get married have kid go get dog year old say massaro millennial say be prioritize pet other thing maybe person generation hold greater esteem idexx most recent quarter be laud analyst share profit rise share revenue grow top view cent respectively accord zack investment research company have see success sedivue industry first clinic urine sediment analyzer recently launch product catalyst sdma clinic test used vet look kidney disease be adopt north american customer first few month debut idexx chief executive ayer contend amazing amazing accomplishment nothing happen fast veterinary tell analyst call adoption rate be typically very slow context adoption sdma slide have be exceptional so re very very pleased success ve have quarterly beat reinforce piper jaffray bullish call companion animal industry william blair analyst say believe long term investment merit idexx remain very compelling beat single line single reference category say canaccord genuity massaro add get extremely strong commercial execution idexx have most savvy sale organization ve ever see point company unusually large direct sale force sale rep north america more europe particular strength share idexx end trading thursday close barely remain buy point share be marginally friday break sharply cup handle base high volume follow company earning report management also lift full year earning guidance cent organic revenue outlook growth currency neutral basis reaffirm sale outlook adjust exchange rate growth even raymond james ransom have high praise company only reaffirm market perform rating same note client cite high price earning multiple hindrance more positive rating come idexx have more occasion push back launch snap fecal dx allow vet test house presence hookworm whipworm roundworm infection canaccord massaro brushed delay view idexx continue crush number raise guide product launch come tell street re beating number startling idexx consistently trade almost time premium multiple other good health care company say massaro example hologic holx medical imaging company call undisputed leader mammography trade time earning vs idexx time earning idexx consistent beat raise quarters model nearly recur revenue unusually high health care number bolster confidence idexx management team have unbelievable grasp business say william blair analyst ryan daniel believe company be durable business franchise warrant premium multiple write early firm be more aggressive share purchase pullback more broadly raymond james ransom say april investor shouldn expect growth ramp end market companion animal diagnostic mean share company idexx abaxis heska be more likely move individual success share gain new product launch etc move uniformly encompass cyclical dynamic give baseline growth rate animal health diagnostic industry canaccord genuity massaro say mean even worst company space grow year really be spectacular industry say be interested medtech stock break zoetis snag billionstock show improve market leadership idexx laboratory earn rs ratingthis top medical stock break beat raise
1,HOLX,think cup handle pattern launch pad great stock use rocket huge price run cup base form handle work well sometimes dynamic moneymaker be too much hurry form handle blast new high savvy investor also know spot cup base form handle slim type investor always first pay tremendous attention company profit revenue profit margin return equity other metric growth don look fundamental vacuum come winning stock trading game precise timing be essence so dangerous actually foolish ignore technical analysis fancy term simply roll sleeve analyze stock behavior chart ignore price volume action be clearly miss significant factor make certain stock great ignore technical mean powerful force supply demand drive stock price day day much longer time period expect cup handle resemble get newsletter deliver inbox more info product service privacy policy term base start develop stock begin decline advance more prior successful be prior demand stock have rise least give price form cup pattern ibd chairman founder bill neil say decline often outpace overall market slide normal growth stock create cup pattern intermediate decline general market correct time market average write best seller make money stock same time want stock show resilience too neil write best choice be generally stock base pattern deteriorate least intermediate market decline re bull market bear market stock downturn exceed time market average be usually too wide loose be regard suspicion want see drop more cup shape severe bear market be deep more still work generally smart focus stock make shallower decline week high cup handle be least week long most be month long span year longer tight price action be preferable wide loose movement addition be more week average volume sign accumulation week fast trade distribution buy point cup base be cent high hit base take shape breakout look stock clear buy point strong turnover meaning trade least day average quickly see day average volume stock go marketsmith view ibd chart gen probe expert diagnostic test blood screening system go public september finished debut week share stock then climb february post solid gain more medical play finally begin first true correction sink high investor be watch see stock clear buy point strong volume tack handle create cup handle base gen probe go first option last trading day april stock gap point barrele past trigger turnover balloon day average right april gen probe show solid ibd rating composite ep rs industry group rs smr sale profit margin return equity accumulation distribution april edition ibd gen probe get featured nasdaq stock news column be now call stock spotlight san diego base firm gain week not cup handle work especially show flaw com wuba form cup handle pull back early december buy point be cent left side high week end jan commerce personal ad network show nice volume stock rise surpass proper entry com rally next week gain fail exceed february market sell stock take lump well fall more trigger most important defensive sell rule investing dove sharply back base editor note version column originally run july edition ibd gen probe be acquire hologic holx august also please follow saito chung twitter ibd_dchung additional commentary stock breakout financial market related master analyze cup handle stock assess merit deep cup handle baselook element excellent handle cup baseinvestor corner crowd be wrong market extremesstock buy big picture stock today
2,HOLX,botox maker allergan agn top wall street second quarter model thursday stock reaction be muted light sale eye drug restasis stagnant revenue fat strip drug kybella second quarter end june allergan report adjust income share sale respective vs year earlier period consensus expect adjust earning share sale allergan also raise guidance revenue adjust income share previously allergan have guide sale adjust earning share raise be unexpected view mizuho analyst irina koffler say note client koffler keep price target buy rating allergan stock stock be hold back mixed performance key product botox cosmetic revenue miss koffler estimate grow year year botox therapeutic bring top koffler view grow allergan cite trade buy pattern stable volume demand decrease sale eye drug restasis number also miss consensus view koffler say ibd take allergan lead medical aesthetic market rival hologic holx dow johnson johnson jnj valeant pharmaceutical vrx have piece sector head industry snapshot closer look layout unit sale linzess increase vs year earlier quarter widely miss street expectation koffler say follow destock first quarter sale kybella injection used improve appearance fat chin be flat juvederm collection sale climb coolsculpt sale be follow close zeltiq acquisition late april stock market today allergan inched less close july share top buy point flat base begin form february related biotech be head deal ceo take rein small biotech launch month high today here biotechs defy downtrend hit fresh high
3,HOLX,stock market close mixed thursday late wave selling erased much day work nasdaq have be close less higher wipe modest gain close fraction lower dow jone industrial average fall less medical company merck mrk johnson johnson jnj pfizer pfe unitedhealth unh be best dow component small cap perform better russell climb downward reversal certainly be not encourage volume be lower board accord preliminary datum suggest institutional investor do not sell massive quantity also negative reversal be not severe scale senate republican unveil own version legislation replace obamacare investor seem mean health care sector medical software drug wholesaler manage care several other medical sector industry group be day best perform rise healthsouth hls break base base pattern close buy point volume be average dampen otherwise bullish move share rise hologic holx break flat base rise past buy point also suffer weak volume relative strength line be new high back day company say win fda approval aptima herpes treatment bankrate rate have better volume break pattern buy point volume be average stock add downside taylor morrison home tmhc gap loss sec filing company say price offer share do not specify price also say filing average sale community month end be home month vs same period net sale order same month rise expect home closing quarter end june be related unitedhealth hca merck rally senate trumpcare bill pare term cut key stock index play buy range biotechs surge again
4,HOLX,amazon com amzn facebook fb broadcom avgo be stock show usaa growth income fund usgrx be smart used oar rather just fund management be divvy team tilt value oriented stock other growth stock last year postelection trump bump lift value oriented stock energy financial bet sector boost fund value oriented sleeve year growth sleeve turn shine brighter year date gain amazon facebook broadcom go thursday stock have add octane growth sleeve fuel so have consumer discretionary name royal caribbean rcl norwegian cruise line nclh likewise health care name hologic holx unitedhealth group unh fund aim split asset growth value sleeve split make sense achieve core fund experience shareholder say usaa wasif latif oversee team run sleeve subadvisor barrow hanley mewhinney strauss run value sleeve house team usaa man growth sleeve most fund dividend come barrow hanley sleeve tandem arrangement have result return month go thursday top large cap blend rival track morningstar inc be so far year fund be vs peer group big cap bogey john jare run growth sleeve john like amazon strength retail web service refer hurricane amazon so disruptive say amazon web service operate margin soar first quarter expect hit end say aw profit grow much faster overall company overall company operate margin be pull aw jare add rapidly grow free cash flow give company more ammunition invest competitor say less enthused amazon takeover whole food market wfm wonder role play amazon future team be crunch number decide investor have oversold other grocery chain fund also own kroger kr jare like way facebook have become magnet advertising dollar largely provide advertiser sharper target consumer see effectiveness ad campaign jare say facebook post additional ad minimal cost attract stock say stock be trading jare say be not range possibility third cruise ship line fund own be carnival ccl cruise line have be tear year say refer cruise ship stock improve demand ve have better pricing last year be problem terrorism europe fear virus improvement employment future economic outlook cruise line have see rise demand ve enjoy easy comp earning comparison last year royal caribbean be so far year earning share grow past quarters ibd take royal caribbean rank leisure service industry group have straight year annual earning share growth norwegian rank group compare stock fundamental technical strength ibd easy use stock checkup tool norwegian trading be year stock be buy range investor look optimal entry point health care jare say team like hologic relatively new ceo stephen macmillan be shift company faster growth profile serve female health diagnostic aesthetic team view unitedhealth be investor have optum division include number fast grow ancillary business improve effectiveness standard insurance business build material maker owen corning oc barrow hanley sleeve be year ep grow past quarters stock have be drive housing rebound strength economy michael nayfa manager barrow hanley sleeve say underlie fundamental remain strong roofing composite business insulation business look set recover housing start remain normal pricing be pick oc remain attractive value trading time normalize earning dividend yield related microsoft surpass amazon web servicesusaa growth income fund show head be better turn glass wine bump ira
5,HOLX,hologic holx stock topple week low thursday firm beat fiscal second quarter sale profit view report lag breast screening revenue note significant disruption cynosure unit late afternoon trading stock market today hologic stock be earlier fall much wednesday close hologic share be year date follow acquisition body sculpting firm cynosure cynosure sale fall year year full quarter hologic cynosure bring beat view canaccord analyst mark massaro modeled blip cynosure sale be due turnover time hologic acquisition company say cite leak deal create significant distraction then hologic have filled vacancy be look add skin tighten future hologic cynosure unit be expect be huge massaro say recent survey doctor core doctor be perform invasive aesthetic procedure today say offer procedure future ibd take hologic acquisition cynosure follow allergan agn acquisition zeltiq day cynosure zeltiq be rival aesthetic business allergan be pull ahead market analyst say head industry snapshot more allergan be dominate market management win quantify opportunity other state be huge write note massaro keep buy rating price target hologic stock note breast health unit stifle quarter hold better fear revenue breast health grow miss consensus view breast imaging used technique call tomosynthesis slow quarter hologic cite political unease decline management note hospital have slow spending base concern potential repeal healthcare reform needham analyst mike matson write note client breast health sale decline growth year earlier quarter international sale accelerate growth matson have buy rating price target hologic stock related hologic smash fiscal sale view beat profit cent
6,HOLX,hologic holx crushed wall street fiscal second quarter revenue profit expectation late wednesday lead double digit growth molecular diagnostic gynecological surgery unit hour trading stock market today hologic stock pop close less share be year follow hologic acquisition body sculpting firm cynosure cynosure be rival zeltiq be recently acquire allergan agn second quarter end april hologic report adjust income cent share revenue earning grow year year basis top cent sale be beat view hologic molecular diagnostic segment lead quarter grow comprise total sale gynecological surgery revenue follow sale skeletal health fall ibd take allergan hold dominant position medical aesthetic market hologic make dent cynosure acquisition head ibd industry snapshot closer look setup quarter hologic sell blood screening business grifol grfs part quarter sale blood screening business bring medical aesthetic unit create cynosure acquisition account related hologic follow allergan buy body sculptor cynosure bil
7,HOLX,fat freeze ear pin breast augment allergan agn isn make expansion medical aesthetic market easy rival hologic holx johnson johnson jnj valeant pharmaceutical vrx analyst say allergan have sunk north aesthetic space add skin cream double chin treatment most recently fat freeze business be just transaction
8,HOLX,hologic holx announce plan acquire body sculpting firm cynosure cyno early tuesday day allergan agn say pay fat freeze zeltiq zltq investor be more forgive allergan purchase hologic stock fall stock market today touch month low cynosure stock lift purchase price share flirt time high cash transaction have enterprise value net cash company say be subject approval cynosure stockholder hologic leader woman health see cynosure ticket medical aesthetic market cynosure portfolio include more product body sculpting hair removal skin revitalization ibd take hologic have middling ibd composite rating meaning outperform nearly quarters stock term key growth metric sale performance only rank company medical system equipment industry group masimo stock lead cr head ibd stock checkup top performer cynosure go obstetric gynecological market make sale revenue be derive market vs traditional plastic surgery dermatology hologic have strong presence ob gyn market deal be expect be immediately accretive earning share ex item add cent grow cent hologic say press release transaction also fill hole left hologic divest blood screening business hologic estimate deal help grow revenue base point increase ep ex item double digit next several year year return interest exceed hologic cost capital company say have identify medical aesthetic attractive complementary growth opportunity strategic plan process be pleased have agree acquire cynosure best class company space hologic ceo steve macmillan say company news release medical aesthetic market be worth more annually globe hologic say monday allergan put price tag body sculpting alone announce plan buy zeltiq used technique freeze fat cell zeltiq stock hit time high response allergan stock close fraction rise tuesday share last week touch month high related hologic still buy get lofty price blood screening unitnew screening rule boost hologic sale growth
9,HOLX,hologic holx flip traditional role late wednesday persuade commercial partner grifol grfs pay lofty hologic decline blood screening business canaccord analyst mark massaro say thursday business get spike year screening overall decline year year be expect be flat massaro write research note core business be secular decline be massaro be surprised see price tag grifol agree pay revenue lofty time multiple write massaro keep buy rating price target hologic stock stock fall thursday likely earning concern hologic blood screening business be expect contribute sale cent earning share ex item deal be expect close hologic say doesn expect fill ep gap next year stock market today hologic share fall cent share remain buy point flat base achieve monday grifol shot gapping day move average still day ibd take hologic be buy zone other stock cutera idexx laboratory be better rate get top medical supplier ibd stock checkup taxe hologic have net proceed help offset ep dilution company use dry powder help pay debt make bolt acquisition repurchase stock massaro say needham analyst mike matson be equally bullish hologic sale note blood screening business have be drag hologic revenue growth blood screening market be experience pricing pressure keep hold rating hologic stock relatednew screening rule boost hologic sale blood screening test hologic grifol get fda nod
10,HOLX,diamondback energy fang yahoo yhoo unite technology utx hologic holx athenahealth athn pier pir release stock move news late wednesday diamondback energy agree pay cash share acquire interest net acre low cost permian basin have see surge drill activity deal worth give diamondback leasehold interest related asset privately hold brigham resource operate llc brigham resource midstream llc diamondback affiliate viper energy partner vnom have be most aggressive buyer asset oil bust begin soon deal be announce diamondback say offer share debt share drop late close yahoo disclose unauthorized third party august steal datum associate more user account yahoo say culprit hasn be identify say be likely distinct mass hack disclose september company blame state sponsored attack yahoo core operation be be acquire verizon vz fall late verizon say review situation related yahoo disclose new bigger datum breach verizon deal jeopardy unite technology say see ep vs analyst view well profit target diversify manufacturer also see sale view unite technology share be little change late wednesday close once again just buy point hologic say sell stake blood screening business grifol grfs cash improve financial flexibility say hologic statement deal close hologic share rise late provider cloud base system medical facility see revenue operate income be wall street forecast athenahealth surge hour home furnishing retailer earn cent share exclude cost related plan exit ceo alex crush view cent pier also see ep cent vs view cent pier also name terry london interim ceo share rise late
11,HOLX,more strong gain stock market tuesday deliver plenty new high financial sector technology health care retail name also show strength cloud software vendor citrix system ctxs rise still early stage breaking base buy point citrix compete vmware vmw
12,HOLX,diagnostic company hologic holx get bump stock market friday new requirement screen donate blood virus hologic screening assay procleix develop spanish partner grifol grfs win emergency fda approval june case infection start appear puerto rico month win contract aid development test roche rhhby coba assay also win hhs support back april time fda only require screening blood center puerto rico county florida now disease have spread fda advise blood center associate territory screen evercore isi analyst vijay kumar estimate split grifol expand screening add annual revenue cent ep light heighten investor fear organic revenue trajectory fiscal note today fda update recent decision cigna ci reimburse tomo mammography feel comfortable hologic revenue come street estimate kumar write research note hologic stock rise stock market today grifol stock fall ibd take hologic be solid stock composite rating putt top stock only rank medical system group however group be so strong currently industry group see stock checkup find company lead group related hospital outlay high tech equipment trend higher
13,HOLX,diagnostic company hologic holx spanish partner grifol grfs say monday fda have grant emergency authorization new system screening donate blood virus procleix virus screening assay be approve testing donate blood area southern deem vulnerable virus have already be implicate severe birth defect latin america indigenous case have be report continental mosquito have infected person close puerto rico procleix test be suite nucleic acid technology product develop hologic grifol partnership used screening blood hiv hepatitis west nile virus other pathogen fda decision follow emergency authorization late friday hologic aptima virus assay test individual be show symptom infection have travele infest area emergency authorization allow use long agency consider threat emergency aren same market approval positive financial impact approval be minimal jeffery analyst raj denhoy write friday authorization hologic test be fourth now available use case individual testing be still very limit add however authorization testing blood screening be expect day test have potential be more meaningful presumably refer procleix hologic stock rise stock market today hologic stock hold solid ep rating relative price strength rating have be flounder guidance disappoint investor late april grifol stock have be form saucer handle base early november buy point earning have decline last quarters grifol stock close
14,HOLX,democratic presidential candidate hillary clinton health care plan release weekend have positive impact company medical hardware development market say evercore isi analyst ross muken write research report clinton plan encourage research development spending give boost provider life science tool service used pharmaceutical development add focus generic biosimilar add additional leg growth pharma end market largely continue benefit chromatography agilent thermo fisher scientific tmo water separation player pall dhr muken write potential offset be increase scrutiny drug pricing lead fewer total dollar spend view unlikely stock be currently highly rate ibd metric especially hold highest possible composite rating be trading time high stock close stock market today touch record high friday agilent share fall thermo fisher also lose water ease clinton also want clear backlog generic drug application fda shorten year exclusivity period grant biosimilar drug muken say accelerate production company make drug drive business contract research organization cro additionally plan intention hold drug company accountable require value base study justify high drug price accelerate pharma adoption real world datum service say adoption provide cro avenue growth outside traditional clinical trial outsource be reason highlighted quintile management quintile im health im merger parexel prxl have also name real world datum service growth driver muken note quintile stock middling cr fall monday parexel hold excellent ibd ep rank dip less outlook be more mixed clinical device system hand plan succeed expand number cover life help boost demand thing orthopedic cardiovascular implant focus woman health be positive hologic holx muken write other hand increase pricing pressure already be dog industry player medtronic mdt be already shift value base business model be best position next leg evolution health care space muken write medtronic stock strong cr hit new intraday high monday close hologic stock have be consolidate company go financial turnaround fall
15,HOLX,diagnostic system firm hologic holx be much bad day market friday stifel upgrade buy hold analyst block write hologic be overcome problem lead growth flatten last couple year diligence lead believe hologic transformation
16,HOLX,banking stock continue gain upward momentum thursday action prove exception ub group ub climb pale volume weekly basis stock be poise make best close least year swiss bank see flat revenue second quarter profit jump
17,HOLX,biotech startup get product approve be main hurdle then company face get paid exact science exas find aug fda approve cologuard innovative noninvasive dna screening test colon cancer doctor recommend colon screening person medicare figure be major payer
18,HOLX,general electric ge win food drug administration approval new dimensional breast imaging device be expect provide clearer view carcinoma produce more radiation today device new device increase competition emerge hot medical device category ge develop senoclaire tomosynthesis machine massachusett general hospital
19,HOLX,intuitive surgical isrg stock jump wednesday company say shipment da vinci surgical system rise higher expect growth robotic surgery procedure intuitive be nearly afternoon trading stock market today more month high sunnyvale calif base company late tuesday report
20,HOLX,person purpose make progress leader point talent target
21,HOLX,set course industry have common shift competition need anchor change believe set clear direction denise morrison ceo campbell soup cpb tell ibd
22,HOLX,year serve bold move specific corporate strategy campbell soup product innovation position packaging market expansion
23,HOLX,look ground
24,HOLX,innovation firm be create restaurant style soup oven sauce satisfy trendy taste
25,HOLX,marketing company be push product new asian latin american territory
26,HOLX,think charting deliberate course be old hat morrison parent taught business lesson dole chore family set goal need get do then open table discussion learn deliver result negotiating skill say
27,HOLX,kid want something new bike be tell business plan consider financial aspect morrison say takeaway work something earn get appreciate more
28,HOLX,take aim morrison know early age want lead company craft mission statement lay stand want achieve haven change say really do believe have personal mission
29,HOLX,find support help staffer build skill personal mission morrison press leadership technical training access internal external mentor sponsor say
30,HOLX,narrow focus lawyer turn entrepreneur kevin conroy be nudge ceo role third wave technology molecular diagnostic firm be foundering board member ask take offer advice
31,HOLX,get whole company organized thing
32,HOLX,conroy say now come back point plan company do page
33,HOLX,establish march order drive result firm be buy medical gear firm hologic holx
34,HOLX,make difficult cut conroy take same streamline approach become ceo exact science exas have product development cut back say
35,HOLX,push away distraction business leader chase shiny object meaning go too many opportunity dilute effort
36,HOLX,really have fight urge re entrepreneur conroy say give employee clear objective boost result
37,HOLX,unite power purpose study pr firm burson marsteller business school imd find identify etre be essential engage employee especially scenario leadership change follow merger refresh brand person purpose make progress leader point talent target set course industry have common shift competition need anchor change believe set clear direction denise morrison ceo campbell soup cpb tell ibd year serve bold move specific corporate strategy campbell soup product innovation position packaging market expansion look ground innovation firm be create restaurant style soup oven sauce satisfy trendy taste marketing company be push product new asian latin american territory think charting deliberate course be old hat morrison parent taught business lesson dole chore family set goal need get do then open table discussion learn deliver result negotiating skill say kid want something new bike be tell business plan consider financial aspect morrison say takeaway work something earn get appreciate more take aim morrison know early age want lead company craft mission statement lay stand want achieve haven change say really do believe have personal mission find support help staffer build skill personal mission morrison press leadership technical training access internal external mentor sponsor say narrow focus lawyer turn entrepreneur kevin conroy be nudge ceo role third wave technology molecular diagnostic firm be foundering board member ask take offer advice get whole company organized thing conroy say now come back point plan company do page establish march order drive result firm be buy medical gear firm hologic holx make difficult cut conroy take same streamline approach become ceo exact science exas have product development cut back say push away distraction business leader chase shiny object meaning go too many opportunity dilute effort really have fight urge re entrepreneur conroy say give employee clear objective boost result unite power purpose study pr firm burson marsteller business school imd find identify etre be essential engage employee especially scenario leadership change follow merger refresh brand
38,HOLX,share woman health company hologic holx gap heavy trading stock market thursday activist investor carl icahn buy large position firm
39,HOLX,late wednesday icahn company report own hologic share share outstanding report person acquire position share belief be undervalue state schedule filing security exchange commission report person intend have conversation member hologic management discuss way enhance shareholder value
40,HOLX,analyst say investor unhappiness reach critical level string miss quarters now be good time sort aggressive intervention icahn be know last year help engineer sale imclone eli lilly lly medimmune astrazeneca azn also threaten hostile takeover prevent mylan myl expensive buyout king pharmaceutical ultimately didn happen mylan deny be icahn
41,HOLX,expect investor react very favorably activist involvement holx share management team have be often criticize destroy shareholder value overpay large acquisition such cytyc lesser extent gen probe write analyst glenn novarro rbc capital market client note open
42,HOLX,analyst vijay kumar isi group note hologic have adopt poison pill provision prevent takeover believe management be too unpopular stop major change
43,HOLX,look icahn nominate slate director board remove member management then look create shareholder value sale restructure kumar write email client poison pill act mean stop further acquisition holx share icahn associate do not believe have impact ultimate outcome here be likely too little too late share woman health company hologic holx gap heavy trading stock market thursday activist investor carl icahn buy large position firm late wednesday icahn company report own hologic share share outstanding report person acquire position share belief be undervalue state schedule filing security exchange commission report person intend have conversation member hologic management discuss way enhance shareholder value analyst say investor unhappiness reach critical level string miss quarters now be good time sort aggressive intervention icahn be know last year help engineer sale imclone eli lilly lly medimmune astrazeneca azn also threaten hostile takeover prevent mylan myl expensive buyout king pharmaceutical ultimately didn happen mylan deny be icahn expect investor react very favorably activist involvement holx share management team have be often criticize destroy shareholder value overpay large acquisition such cytyc lesser extent gen probe write analyst glenn novarro rbc capital market client note open analyst vijay kumar isi group note hologic have adopt poison pill provision prevent takeover believe management be too unpopular stop major change look icahn nominate slate director board remove member management then look create shareholder value sale restructure kumar write email client poison pill act mean stop further acquisition holx share icahn associate do not believe have impact ultimate outcome here be likely too little too late
44,HOLX,search slim first seriesibd slim growth stock investing system start good reason stand current earning share sale growth most important factor identify potential winning stock target company post ep growth least year level most recent quarter comparison year figure be used avoid seasonal distortion even better earning growth have accelerate recent quarters go say increase vs year earlier ibd research show biggest winner past year post biggest profit increase quarter take fact stock averaged more profit growth latest quarter right big advance keep mind ep gain be accompany quarterly sale growth least latest period slightly slower accelerate sale gain be acceptable find winner scrutinize sector leader highlighted research table section ibd provide most recent quarterly profit growth figure quarter average earning sale growth chart friday weekly review give most recent quarterly ep change monday ibd tuesday big cap chart hold quarters datum investor com be good place look potential winner stock checkup section provide datum most recent quarter sale profit growth average growth past quarters number quarters ep growth acceleration note rise profit accompany slow sale be red flag indicate earning be grow cost cut rather new product strategy also couple quarters drastically slow profit growth be sell signal hologic holx make medical diagnostic equipment break buy point cup base week end nov more double average daily volume come company report jump quarterly earning follow whopping increase respectively prior quarters increase marked second straight quarter deceleration result be still strong be especially robust compare jump year quarter hologic sale rise modest quarter prior marked third straight quarter accelerate growth stock rally february
45,HOLX,myriad genetic mygn be hit multiple analyst downgrade monday plunge stock market today center medicare medicaid service confirm weekend cut reimbursement myriad genetic test breast cancer vulnerability myriad be morning trading monday week low late friday cms say start
46,HOLX,share hologic holx jump week high early wednesday medical imaging company new study support mammography technology
47,HOLX,interim analysis mammogram find used combination have better detection rate lower false positive rate used alone hologic sell system call selenia new study help reimbursement negotiation medicare medicaid say isi group analyst
48,HOLX,recall lack statistical significance cancer detection have be raise concern investor rsna radiological society north america conference analyst ross muken vijay kumar write email client late tuesday radiologist have state have see improve cancer detection anecdotally interim result further support superiority tomo
49,HOLX,however email early wednesday analyst write bear be say real world recall rate number patient call back test usually false positive drop less presumably call question cost saving technology muken kumar disagree perhaps explain volatility stock wednesday early trading jump more top first time first hour trading conclude be back just share hologic holx jump week high early wednesday medical imaging company new study support mammography technology interim analysis mammogram find used combination have better detection rate lower false positive rate used alone hologic sell system call selenia new study help reimbursement negotiation medicare medicaid say isi group analyst recall lack statistical significance cancer detection have be raise concern investor rsna radiological society north america conference analyst ross muken vijay kumar write email client late tuesday radiologist have state have see improve cancer detection anecdotally interim result further support superiority tomo however email early wednesday analyst write bear be say real world recall rate number patient call back test usually false positive drop less presumably call question cost saving technology muken kumar disagree perhaps explain volatility stock wednesday early trading jump more top first time first hour trading conclude be back just
50,HOLX,spot fine chart first seriesnot cup be alike sometimes difference jump subtle detail trip first new corner series assess quality stock base pattern ll examine left side cup shouldn look simply put cup left side be place panic left side cup appear stock fall do want see big volume steep retreat unmistakable stink panic certainly not re look calm decline serious volume surge stock shouldn just collapse old build rather decline be orderly do care stock fall don yet own answer re still shopping re tracking professional big money fund manager bring stock first place dramatic high volume sell off be footprint manager dump much fast have be base hunting time ll have noticed volume increase cup left side be hard avoid don huge scary surge now let say cup left side show such panic look stock weekly chart re look weekly close upper weekly range show fund be likely add position even way want see big guy get not hologic holx build week consolidation start week end july left side appear straight weekly loss volume biggest surge appear week trade climb usual pace not much medical gear maker end week loss just few penny upper trading range week show hologic first weekly gain cup begin fact stock have slice week move average then regain post upside reversal show hand big fund accumulate share coincidence stock bottom just week later
51,HOLX,stock hung break even line ahead tuesday lunch hour morning big winner loser stick early move
52,HOLX,nasdaq dow jone industrial average dip apiece
53,HOLX,trade turn higher stock market today nasdaq volume reverse early decline climb nyse volume also strengthen level same time monday
54,HOLX,medical imaging equipment maker hologic holx tank earning squeak past view fiscal fourth quarter revenue growth didn measure management earning revenue guidance first quarter full year also undercut expectation stock have break moderate trade orderly cup handle base monday
55,HOLX,rackspace host rax topple trip expect dive earning provider cloud base compute power revenue inched past estimate cost rise quarter stock slide slice week line support stall effort recover june low
56,HOLX,china base stock be morning most active lead vipshop holding vip spiked third quarter earning soar past consensus expectation revenue growth stop short forecast flash sale online retailer lift revenue guidance well estimate big volume gain send share new high follow test week support late october
57,HOLX,bitauto holding bita surge heavy trade help partly china strong auto sale number october stock have be consolidate oct high week move average early october stock hung break even line ahead tuesday lunch hour morning big winner loser stick early move nasdaq dow jone industrial average dip apiece trade turn higher stock market today nasdaq volume reverse early decline climb nyse volume also strengthen level same time monday medical imaging equipment maker hologic holx tank earning squeak past view fiscal fourth quarter revenue growth didn measure management earning revenue guidance first quarter full year also undercut expectation stock have break moderate trade orderly cup handle base monday rackspace host rax topple trip expect dive earning provider cloud base compute power revenue inched past estimate cost rise quarter stock slide slice week line support stall effort recover june low china base stock be morning most active lead vipshop holding vip spiked third quarter earning soar past consensus expectation revenue growth stop short forecast flash sale online retailer lift revenue guidance well estimate big volume gain send share new high follow test week support late october bitauto holding bita surge heavy trade help partly china strong auto sale number october stock have be consolidate oct high week move average early october
58,HOLX,johnson johnson offer investor first look state medical industry modestly beat consensus estimate raise guidance share rise nearly early trading eventually close fraction johnson johnson jnj make share year earlier quarter beating
59,HOLX,share intuitive surgical isrg gap tuesday morning month low analyst downgrade stock follow company warning
60,HOLX,late monday maker da vinci surgical system announce preliminary result include drop system revenue be partly offset grow revenue instrument accessory service overall sale fall woefully short analyst consensus number
61,HOLX,decline system sale be impact several factor include other thing increase economic pressure hospital turn cause defer da vinci system purchase moderate growth benign gynecologic procedure say company press release
62,HOLX,goldman sachs jmp security canaccord genuity downgrade stock neutral equivalent
63,HOLX,capital equipment business look be face material incremental head wind goldman analyst david roman write report tuesday addition management commentary payor be start encourage more conservative care well treatment outpatient setting be new dynamic have not previously contemplated thesis stock
64,HOLX,negative comment hospital spending have push several other stock ibd medical system group heavy volume stock market tuesday morning trading varian medical system var be more be hologic holx carefusion cfn sell mainly exclusively hospital share intuitive surgical isrg gap tuesday morning month low analyst downgrade stock follow company warning late monday maker da vinci surgical system announce preliminary result include drop system revenue be partly offset grow revenue instrument accessory service overall sale fall woefully short analyst consensus number decline system sale be impact several factor include other thing increase economic pressure hospital turn cause defer da vinci system purchase moderate growth benign gynecologic procedure say company press release goldman sachs jmp security canaccord genuity downgrade stock neutral equivalent capital equipment business look be face material incremental head wind goldman analyst david roman write report tuesday addition management commentary payor be start encourage more conservative care well treatment outpatient setting be new dynamic have not previously contemplated thesis stock negative comment hospital spending have push several other stock ibd medical system group heavy volume stock market tuesday morning trading varian medical system var be more be hologic holx carefusion cfn sell mainly exclusively hospital
65,HOLX,woman health specialist hologic holx announce early monday buy venereal disease testing company gen probe gpro also report quarterly revenue bit short estimate gen probe stock soar early monday announcement hologic pay share cash premium friday close price press release announce
66,HOLX,just look align technology algn have perfect tech invisible brace company find yet way improve early year san jose calif maker alternative metal brace introduce new material invisalign clear aligner system smarttrack highly elastic material better maintain
67,HOLX,stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute
68,HOLX,dow jone industrial nasdaq climb grab gain
69,HOLX,volume be quietly mixed nasdaq lower nyse relative trade same time tuesday
70,HOLX,stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase
71,HOLX,dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list
72,HOLX,norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more
73,HOLX,conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year
74,HOLX,base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly
75,HOLX,array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum
76,HOLX,china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result
77,HOLX,leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average
78,HOLX,citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute dow jone industrial nasdaq climb grab gain volume be quietly mixed nasdaq lower nyse relative trade same time tuesday stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base
79,HOLX,thermo fisher scientific tmo maker instrument test used analyze lab sample early monday say buy privately hold transplant testing company lambda
80,HOLX,purchase help thermo fisher expand specialty diagnostic market
81,HOLX,lambda be exciting addition specialty diagnostic portfolio thermo fisher ceo marc casper say company press release
82,HOLX,employee lambda make product used transplant center test tissue mainly determine compatibility potential transplant donor recipient test be design detect presence antibody lead transplant rejection
83,HOLX,thermo fisher say deal add cent cent earning share item share waltham mass base thermo fisher be fraction early trading monday stock have fall past year
84,HOLX,view deal positively strategic financial perspective isi group analyst ross muken write report say strengthen thermo fisher specialty diagnostic field call price reasonable boost fiscal share profit estimate also raise stock price target
85,HOLX,reuter note deal be thermo fisher third biggest acquisition year follow string other deal diagnostic sector
86,HOLX,agilent technology announce buy danish cancer diagnostic company dako april hologic holx say april buy gen probe
87,HOLX,thermo fisher buy sweden base diagnostic firm phadium last year thermo fisher scientific tmo maker instrument test used analyze lab sample early monday say buy privately hold transplant testing company lambda purchase help thermo fisher expand specialty diagnostic market lambda be exciting addition specialty diagnostic portfolio thermo fisher ceo marc casper say company press release employee lambda make product used transplant center test tissue mainly determine compatibility potential transplant donor recipient test be design detect presence antibody lead transplant rejection thermo fisher say deal add cent cent earning share item share waltham mass base thermo fisher be fraction early trading monday stock have fall past year view deal positively strategic financial perspective isi group analyst ross muken write report say strengthen thermo fisher specialty diagnostic field call price reasonable boost fiscal share profit estimate also raise stock price target reuter note deal be thermo fisher third biggest acquisition year follow string other deal diagnostic sector agilent technology announce buy danish cancer diagnostic company dako april hologic holx say april buy gen probe thermo fisher buy sweden base diagnostic firm phadium last year
88,HOLX,hologic holx top fourth quarter expectation business unit grow sale guidance future result be cautious developer imaging surgical gear say hour earn cent share year penny better wall street estimate revenue rise forecast
89,HOLX,several top rate medical technology company report better expect earning late thursday share generally fall various concern range european weakness rise cost intuitive surgical isrg maker da vinci robotic surgery system beat analyst quarterly estimate quarter row sale climb year earlier
90,HOLX,stock open lower monday follow expect economic news worry spain nasdaq drop dow jone industrial average slip just drop boee ba be softened gain ibm ibm merck mrk volume be tracking sharply lower nasdaq touch lower
91,HOLX,stock step red ink early monday earning report weak december consumer spending datum overseas loss weigh slump gannett gci staple spls wynn resort wynn rac heavy loss nasdaq dow jone industrial average dip trading be lower nasdaq
92,HOLX,major index fall tuesday hold most big gain monday want hear ibd analysis today market emerge stock click here watch latest market wrap video nasdaq give nyse dow slip volume nasdaq open lower picked
93,HOLX,update market friday neither extend contest thursday rally confirmation notch positive finish lower volume
94,HOLX,health care issue lead day nyse healthcare index post gain nasdaq biotech sector jump insurance component surge
95,HOLX,accord preliminary calculation nasdaq index packed gain week nyse composite plow ahead dow throw advance thursday big volume gain turn market correction confirm rally signal buyer back market recommend only cautious buy rally prove intent
96,HOLX,monday analyst expect industrial production capacity utilization number federal reserve show fifth straight month decline new york fed be schedule release empire state manufacturing survey number march set datum be due market open
97,HOLX,keep eye houston wire cable hwcc landry restaurant lny sterling construction strl plan announce earning prior market open china base internet content provider sina sina be tap report hour
98,HOLX,update index cap strong week close day high
99,HOLX,juan carlos arancibia
100,HOLX,market close higher fight midday weakness
101,HOLX,nasdaq rise nyse composite dow be close bell
102,HOLX,index erased midday loss afternoon advance major average close session high
103,HOLX,volume be lower trading slow afternoon dealing
104,HOLX,number medical industry group be day best performer
105,HOLX,update techs lag med stock rock late trade
106,HOLX,update market friday neither extend contest thursday rally confirmation notch positive finish lower volume health care issue lead day nyse healthcare index post gain nasdaq biotech sector jump insurance component surge accord preliminary calculation nasdaq index packed gain week nyse composite plow ahead dow throw advance thursday big volume gain turn market correction confirm rally signal buyer back market recommend only cautious buy rally prove intent monday analyst expect industrial production capacity utilization number federal reserve show fifth straight month decline new york fed be schedule release empire state manufacturing survey number march set datum be due market open keep eye houston wire cable hwcc landry restaurant lny sterling construction strl plan announce earning prior market open china base internet content provider sina sina be tap report hour update index cap strong week close day high juan carlos market close higher fight midday weakness nasdaq rise nyse composite dow be close bell index erased midday loss afternoon advance major average close session high volume be lower trading slow afternoon dealing number medical industry group be day best performer update techs lag med stock rock late trade
107,HOLX,update major index close high trading range strong manufacturing datum soft dollar boost energy commodity lead market
108,HOLX,nyse composite perked swung higher be biggest jump index jan
109,HOLX,dow nasdaq composite climb lower gear respectively
110,HOLX,volume remain soft session provide little fodder bull
111,HOLX,hour rent center rcii rise top consensus sale earning estimate rent own furniture appliance chain report earning sale be still mired quarterly decline
112,HOLX,medical imaging diagnostic equipment maker hologic holx jump close also top analyst sale earning view report decline category fiscal second quarter company offer line earning guidance put revenue consensus company also raise fiscal outlook
113,HOLX,earning schedule tuesday open include american superconductor amsc ctrip com international ctrp dow chemical dow hsy kraft food kft netlogic microsystem netl
114,HOLX,also tuesday december pending home sale be set release january vehicle sale also be
115,HOLX,stock close higher lighter volume
116,HOLX,patrick
117,HOLX,update market start february higher low volume indicated lack conviction
118,HOLX,dow monday add nasdaq nyse composite bolster strong commodity volume fall board
119,HOLX,big winner day be valassis communication vci gap fly big move come news corp nws subsidiary agree pay advertiser settle antitrust suit
120,HOLX,downside idexx laboratory idxx continue sell start release earning friday monday stock fall more time normal trade top fall friday do find support day move average
121,HOLX,stock stay hot light volume
122,HOLX,patrick
123,HOLX,stock hold early session gain volume stay dry
124,HOLX,dow rise nasdaq nyse composite
125,HOLX,ash maker resin adhesive polymer rise high volume action come company recieve upgrade stifel nicolaus analyst boost stock buy rating previous stance hold
126,HOLX,company have wild earning history last quarter profit soar quarter earning be massive turnaround quarter however wall street expect just earning rise
127,HOLX,spanish information technology firm telvent tlvt grow stock be second straight day gain average trade last week stock slip week move average line now trading once again
128,HOLX,cheesecake factory cake restaurant chain add stock be currently consolidate tricky base base pattern first base be september december shallow cup break then settle flat base first rise least
129,HOLX,second base begin week dec be intra week high be higher left side base weekly close high have not surpass close week dec
130,HOLX,stock improve afternoon trade
131,HOLX,vincent mao
132,HOLX,update major index continue push ahead afternoon trading monday
133,HOLX,nyse composite jump dow thank chip stock nasdaq also improve gain philadelphia semiconductor index rally recoup bulk friday loss
134,HOLX,amedisys am reversed morning loss run fast trade last month firm sign deal health insurer humana hum provide home health service
135,HOLX,panera bread pnra erased earlier loss rise nearly heavy trading also erased friday decline operator baker cafe report earning feb analyst see profit rise cent share
136,HOLX,elsewhere pullback dollar lift gold april contract climb ounce
137,HOLX,gold producer also shine
138,HOLX,silver wheaton slw climb erase loss past session
139,HOLX,buenaventura bvn jaguar mining jag gain
140,HOLX,index hold gain commodity strength
141,HOLX,alan elliott
142,HOLX,update commodity industrial issue hold major index high volume remain slower enter afternoon trading
143,HOLX,nyse composite lead gain be dow add nasdaq composite rise warner chilcott wcrx amazon com amzn post big loss
144,HOLX,dow transport be airline railroad fedex fdx grab gain moderate trading dow exxon mobil xom jpmorgan jpm take better gain average trading
145,HOLX,iron ore producer cliff natural resource clf jump strong trade mark biggest advance coal miner massey energy consul energy cnx be close
146,HOLX,seagate technology stx jump heavy trade move put datum storage hardware maker back week move average follow big volume sell last week
147,HOLX,pegasystem pega grab gain very busy trading maker business process software include cloud compute product break cup handle buy point last week then drop mark be now bounce support week move average
148,HOLX,downside arkansa base home bancshare homb tank massive trade announce ron company president chief operate officer die sunday home bancshare be part southwestern bank group accelerate ranking past week
149,HOLX,most index extend gain
150,HOLX,vincent mao
151,HOLX,update most stock index marched new session high brief pullback
152,HOLX,nyse composite climb dow nasdaq rise do not hit new intraday high volume be tracking lower exchange
153,HOLX,seagate technology stx rally regain day move average stock drop friday biggest downside volume year seagate accumulation distribution rating have wane earlier month
154,HOLX,give imaging givn reversed earlier loss turn fractionally higher have be more pace snap session slide
155,HOLX,downside amazon com amzn extend earlier loss tumble lowest level more month
156,HOLX,lubrizol lz fall further south day line share gap drop heavy trading citigroup cut chemical maker sell hold margin concern stock pass buy point cup base jan have now fall more trigger exception sell rule
157,HOLX,stock strengthen morning trade
158,HOLX,vincent mao
159,HOLX,update stock add gain morning mixed economic datum
160,HOLX,thank energy steel gold stock nyse composite lead gain climb dow meanwhile nasdaq gain
161,HOLX,turnover be again tracking lower exchange
162,HOLX,american superconductor amsc rally news win order worth wind turbine control system company report fiscal earning tuesday analyst be expect profit cent share
163,HOLX,baidu bidu rise regain day move average credit suisse raise chinese internet search firm neutral underperform
164,HOLX,downside warner chilcott wcrx gap day move average drop downgrade morgan stanley cut drugmaker equalweight overweight
165,HOLX,stock open higher
166,HOLX,vincent mao
167,HOLX,update stock rushed gate monday make portion friday loss
168,HOLX,nyse composite climb dow nasdaq
169,HOLX,volume be tracking sharply lower board
170,HOLX,economic news ism manufacturing index january come much strong expect read economist expect read
171,HOLX,meanwhile construction spending december drop vs expectation decline
172,HOLX,valassis communication vci gap fly huge volume news corp nws subsidiary agree pay advertiser settle antitrust suit
173,HOLX,akamai akam gap gain upgrade wedbush morgan raise share outperform neutral
174,HOLX,sandisk sndk rise regain day move average bounce back session sell last week flash memory maker report result view sale outlook disappoint
175,HOLX,downside amazon com amzn fall fast trade weekend commerce giant give publisher macmillan concession higher book price
176,HOLX,stock track higher start
177,HOLX,vincent mao
178,HOLX,update future signale higher open monday stock look bounce back last month sell
179,HOLX,future rally point vs fair value nasdaq future gain point dow future climb point
180,HOLX,economic news personal income rise december beating estimate gain personal spending rise third straight month be tad economist estimate future barely budge miss
181,HOLX,datum construction spending ism manufacturing index be
182,HOLX,earning front exxonmobil xom gain pre open trade better expect earning integrate oil giant profit fall year earlier share still top view cent sale rise also view
183,HOLX,humana hum report mixed result health insurer earning rise share match wall street estimate sale edge only view partly due temporary contract extension humana raise profit guidance range share still also consensus estimate share share fall nearly pre market trading
184,HOLX,elsewhere urban outfitter urbn replace affiliated computer system acs index be announce date affiliated computer be be buy xerox xrx urban outfitter climb pre market trade
185,HOLX,fertilizer producer intrepid potash ipi take urban outfitter place midcap also gain pre open activity
186,HOLX,dollar slip month high euro gold oil edge higher
187,HOLX,future point higher open
188,HOLX,vance cariaga
189,HOLX,update stock future point higher open monday wall street look begin february high note finishing january negative territory
190,HOLX,future rise point pre market be fair value dow future gain point nasdaq future add point
191,HOLX,commerce department report personal spending income be due economist project spending rise december rise november income be also expect have rise climb november
192,HOLX,government release datum construction spending december analyst expect spending fall drop november
193,HOLX,also institute supply management january manufacturing index be due economist expect read january december read mean sector be grow
194,HOLX,investor also keep eye nation capital white house send congress budget proposal anticipate record set budget deficit
195,HOLX,earning news exxonmobil xom be most prominent company due report result today
196,HOLX,toyota motor tm unveil plan fix gas pedal more vehicle be recall pedal get stick be slow return release increase risk crash
197,HOLX,elsewhere yield benchmark year treasury note rise early monday late friday yield month bill climb dollar mostly rise other major currency gold price fall
198,HOLX,overseas japan nikkei stock average rise hong kong hang seng add afternoon trade britain ftse gain germany dax index climb france cac update major index close high trading range strong manufacturing datum soft dollar boost energy commodity lead market nyse composite perked swung higher be biggest jump index jan dow nasdaq composite climb lower gear respectively volume remain soft session provide little fodder bull hour rent center rcii rise top consensus sale earning estimate rent own furniture appliance chain report earning sale be still mired quarterly decline medical imaging diagnostic equipment maker hologic holx jump close also top analyst sale earning view report decline category fiscal second quarter company offer line earning guidance put revenue consensus company also raise fiscal outlook earning schedule tuesday open include american superconductor amsc ctrip com international ctrp dow chemical dow hsy kraft food kft netlogic microsystem netl also tuesday december pending home sale be set release january vehicle sale also be stock close higher lighter volumeby patrick update market start february higher low volume indicated lack conviction dow monday add nasdaq nyse composite bolster strong commodity volume fall board big winner day be valassis communication vci gap fly big move come news corp nws subsidiary agree pay advertiser settle antitrust suit downside idexx laboratory idxx continue sell start release earning friday monday stock fall more time normal trade top fall friday do find support day move average stock stay hot light volumeby patrick stock hold early session gain volume stay dry dow rise nasdaq nyse composite ash maker resin adhesive polymer rise high volume action come company recieve upgrade stifel nicolaus analyst boost stock buy rating previous stance hold company have wild earning history last quarter profit soar quarter earning be massive turnaround quarter however wall street expect just earning rise spanish information technology firm telvent tlvt grow stock be second straight day gain average trade last week stock slip week move average line now trading once again cheesecake factory cake restaurant chain add stock be currently consolidate tricky base base pattern first base be september december shallow cup break then settle flat base first rise least second base begin week dec be intra week high be higher left side base weekly close high have not surpass close week dec stock improve afternoon tradeby vincent mao update major index continue push ahead afternoon trading monday nyse composite jump dow thank chip stock nasdaq also improve gain philadelphia semiconductor index rally recoup bulk friday loss amedisys am reversed morning loss run fast trade last month firm sign deal health insurer humana hum provide home health service panera bread pnra erased earlier loss rise nearly heavy trading also erased friday decline operator baker cafe report earning feb analyst see profit rise cent share elsewhere pullback dollar lift gold april contract climb ounce gold producer also shine silver wheaton slw climb erase loss past session buenaventura bvn jaguar mining jag gain index hold gain commodity strengthby alan elliott update commodity industrial issue hold major index high volume remain slower enter afternoon trading nyse composite lead gain be dow add nasdaq composite rise warner chilcott wcrx amazon com amzn post big loss dow transport be airline railroad fedex fdx grab gain moderate trading dow exxon mobil xom jpmorgan jpm take better gain average trading iron ore producer cliff natural resource clf jump strong trade mark biggest advance coal miner massey energy consul energy cnx be close seagate technology stx jump heavy trade move put datum storage hardware maker back week move average follow big volume sell last week pegasystem pega grab gain very busy trading maker business process software include cloud compute product break cup handle buy point last week then drop mark be now bounce support week move average downside arkansa base home bancshare homb tank massive trade announce ron company president chief operate officer die sunday home bancshare be part southwestern bank group accelerate ranking past week most index extend gainsby vincent mao update most stock index marched new session high brief pullback nyse composite climb dow nasdaq rise do not hit new intraday high volume be tracking lower exchange seagate technology stx rally regain day move average stock drop friday biggest downside volume year seagate accumulation distribution rating have wane earlier month give imaging givn reversed earlier loss turn fractionally higher have be more pace snap session slide downside amazon com amzn extend earlier loss tumble lowest level more month lubrizol lz fall further south day line share gap drop heavy trading citigroup cut chemical maker sell hold margin concern stock pass buy point cup base jan have now fall more trigger exception sell rule stock strengthen morning tradeby vincent mao update stock add gain morning mixed economic datum thank energy steel gold stock nyse composite lead gain climb dow meanwhile nasdaq gain turnover be again tracking lower exchange american superconductor amsc rally news win order worth wind turbine control system company report fiscal earning tuesday analyst be expect profit cent share baidu bidu rise regain day move average credit suisse raise chinese internet search firm neutral underperform downside warner chilcott wcrx gap day move average drop downgrade morgan stanley cut drugmaker equalweight overweight stock open higherby vincent mao update stock rushed gate monday make portion friday loss nyse composite climb dow nasdaq volume be tracking sharply lower board economic news ism manufacturing index january come much strong expect read economist expect read meanwhile construction spending december drop vs expectation decline valassis communication vci gap fly huge volume news corp nws subsidiary agree pay advertiser settle antitrust suit akamai akam gap gain upgrade wedbush morgan raise share outperform neutral sandisk sndk rise regain day move average bounce back session sell last week flash memory maker report result view sale outlook disappoint downside amazon com amzn fall fast trade weekend commerce giant give publisher macmillan concession higher book price stock track higher startby vincent mao update future signale higher open monday stock look bounce back last month sell future rally point vs fair value nasdaq future gain point dow future climb point economic news personal income rise december beating estimate gain personal spending rise third straight month be tad economist estimate future barely budge miss datum construction spending ism manufacturing index be earning front exxonmobil xom gain pre open trade better expect earning integrate oil giant profit fall year earlier share still top view cent sale rise also view humana hum report mixed result health insurer earning rise share match wall street estimate sale edge only view partly due temporary contract extension humana raise profit guidance range share still also consensus estimate share share fall nearly pre market trading elsewhere urban outfitter urbn replace affiliated computer system acs index be announce date affiliated computer be be buy xerox xrx urban outfitter climb pre market trade fertilizer producer intrepid potash ipi take urban outfitter place midcap also gain pre open activity dollar slip month high euro gold oil edge higher future point higher openby vance cariaga update stock future point higher open monday wall street look begin february high note finishing january negative territory future rise point pre market be fair value dow future gain point nasdaq future add point commerce department report personal spending income be due economist project spending rise december rise november income be also expect have rise climb november government release datum construction spending december analyst expect spending fall drop november also institute supply management january manufacturing index be due economist expect read january december read mean sector be grow investor also keep eye nation capital white house send congress budget proposal anticipate record set budget deficit earning news exxonmobil xom be most prominent company due report result today toyota motor tm unveil plan fix gas pedal more vehicle be recall pedal get stick be slow return release increase risk crash elsewhere yield benchmark year treasury note rise early monday late friday yield month bill climb dollar mostly rise other major currency gold price fall overseas japan nikkei stock average rise hong kong hang seng add afternoon trade britain ftse gain germany dax index climb france cac
199,HOLX,stock be quiet market close major index close higher week friday sell notable earning report expect late evening be petroleo brasileiro pbr brazilian natural gas oil company be former market leader week dow climb nyse composite nasdaq market open monday co tif be schedule report result jewelry firm have see earning fall quarters straight sale have drop straight quarters current period analyst expect profit share week break cup shape base volume be barely average also open report industrial production be due consensus estimate be month month production change be flat utilization rate slip stock tumble volume surge
200,HOLX,update main index continue monday major index fumble open bell worsen day progressed close session lows
201,HOLX,nyse composite drop nasdaq breach respective day move average dow pierce day line friday lose citigroup be biggest loser blue chip index gap tumble heavy trade analyst concern just much more money struggle bank need offset news continue talk regard sale barney brokerage unit morgan stanley ms
202,HOLX,volume rise nyse fall nasdaq decliner beat advancer nyse nasdaq
203,HOLX,once again gain dwindle several recent breakout
204,HOLX,aecom technology acm shed heavy volume close buy point government contractor have now give gain dec then
205,HOLX,sxc health solution sxci drop nearly twice average trade provider pharmacy benefit management service fall winning big contract sxc finished day move average buy point
206,HOLX,life partner holding lphi fall brisk trade company deal life settlement contract report earning tuesday profit be slate rise cent share
207,HOLX,upside apollo group apol add nearly active turnover school operator earning growth accelerate recent quarters
208,HOLX,update main index log weak session
209,HOLX,juan carlos arancibia
210,HOLX,main index continue monday
211,HOLX,nasdaq slide nyse composite dow close bell
212,HOLX,volume rise nyse give dow nyse composite yet distribution day trading slow nasdaq accord early reading
213,HOLX,energy sector faltered crude price tumble again
214,HOLX,financial also sputter analyst warn bank america bac post loss again cut dividend bofa share skid citigroup plunge worry performance
215,HOLX,update volume gain index sniff new lows
216,HOLX,alan elliott
217,HOLX,fall financial issue overtake slide energy sector stock index carry deeper loss final hour trading
218,HOLX,nyse composite stab loss financial index drag vs drop energy index nasdaq composite tumble sag dow slump
219,HOLX,nyse volume continue strengthen nasdaq volume hold friday average level
220,HOLX,tumble gap gain advanced medical optic eye medical product heavyweight abbot laboratory say acquire cataract related product maker
221,HOLX,medical software maker cerner cern jump heavy trading put share back day move average stock try build way month consolidation
222,HOLX,masimo masi haul gain better double average volume maker patient monitoring equipment fall prior session remain deep month correction
223,HOLX,nymex show crude future trading lower barrel ice future exchange show february brent crude london edge cent lower barrel analyst be report supply glut nymex pricing hub cush okla do not reflect global supply demand balance
224,HOLX,update stock remain lower volume mixed
225,HOLX,patrick
226,HOLX,stock sprang back session lows remain lower
227,HOLX,dow be nasdaq nyse be
228,HOLX,volume be higher nyse lower nasdaq
229,HOLX,martin marietta mlm seller rock gravel other construction supply fall analyst downgrade stock sell neutral
230,HOLX,company earning last quarters have decline stock recently start rise president elect barack obama plan improve infrastructure fuel business
231,HOLX,coca cola femsa kof drop bottler coca cola slice day move average begin last week stock be more
232,HOLX,upside thinly trade american italian pasta aipc gain spaghettus stock jump last week then fall hard only recover squeak gain week
233,HOLX,ensign group ensg nursing home assist live home operator be break even diving stock find support day move average
234,HOLX,update stock bounce back midday trade
235,HOLX,vincent mao
236,HOLX,extend loss major stock index try rebound midday monday
237,HOLX,nyse composite trim deficit nasdaq lose dow fall milder citigroup alcoa aa bank america bac be biggest percentage loser blue chip index
238,HOLX,turnover be again tracking mixed nyse volume higher nasdaq lower
239,HOLX,celgene celg fall guide earning sale view exclude item biotech expect full year profit range share vs analyst estimate revenue be peg vs view
240,HOLX,tower group twgp drop brisk volume extend friday decline stock have give back most gain dec cup handle
241,HOLX,southwestern energy swn lose be upgrade standard poor raise oil gas producer hold sell cite positive development fayetteville shale operation
242,HOLX,update stock hit new session lows
243,HOLX,vincent mao
244,HOLX,comeback effort faltered monday halftime send major index new intraday lows
245,HOLX,nyse composite tumble drag oil related issue crude oil drop barrel nasdaq pierce day move average drop meanwhile lose dow
246,HOLX,volume be tracking bit higher nyse lower nasdaq decliner beat advancer nyse slightly less nasdaq
247,HOLX,cubist pharmaceutical cbst gap day move average drop report sale view drug maker say full year sale come vs analyst estimate
248,HOLX,aecom technology acm drop continue give back gain december government contractor now sit past buy point have be nearly
249,HOLX,upside mover heavy volume be few
250,HOLX,aaron rent rnt rise erased bulk friday loss furniture appliance rental firm enter ibd week
251,HOLX,update index lows hold soft outlook
252,HOLX,alan elliott
253,HOLX,ripple concern weaken consumer demand run world market monday drive stock commodity lower asia europe market index hold just lows weak trading action
254,HOLX,nyse composite dig loss heavily weight energy index lead downside sank nasdaq composite dow shed
255,HOLX,volume remain sharply lower nasdaq slightly nyse vs friday average trading nyse average volume nasdaq
256,HOLX,february crude contract slip barrel london brent crude shed hold barrel analyst expect wider divergence next several week crude brent crude european benchmark due unusually high stockpile particularly weak demand cush okla nymex pricing hub light sweet crude
257,HOLX,most upside stock post only modest gain research publish group ihs ihs eke private college operator apollo group apol nudge gain medical device maker thoratec thor grab advance
258,HOLX,hologic holx power gain heavy trading maker medical imaging system lower revenue estimate raise ep guidance analyst view moved earn stock upgrade hold buy jeffery co hologic remain deep yearlong consolidation
259,HOLX,downside footwear maker decker outdoor deck dive big trade fall day move average move put dent stock effort build way month consolidation
260,HOLX,overseas market asia trade generally lower shanghai composite edge modest hong kong hang seng index tumble close week low tokyo nikkei japan be close monday holiday
261,HOLX,stock moved decisively lower europe commodity pull back sharply ftse london dip frankfurt dax take loss cac index paris retract
262,HOLX,update stock open lower mixed trade
263,HOLX,vincent mao
264,HOLX,stock open lower monday try rebound quickly get shot
265,HOLX,nyse composite breach day move average fall respectively dow slip further south day line decline nasdaq also lose remain day move average
266,HOLX,volume be tracking sharply higher nyse vastly lower nasdaq
267,HOLX,landry restaurant lry gap plunge cancel plan go private operator rainforest cafe saltgrass steak house chain instead pursue refinancing senior debt
268,HOLX,kennametal kmt gap shed announce round layoff lower profit outlook maker engineer component cut job next few month also cut fiscal earning guidance range cent share prior range cent cent
269,HOLX,harley davidson hog gap tumble goldman sachs cut motorcycle manufacturer sell neutral goldman cite potential downside impact luxury motorcycle market
270,HOLX,update stock poise soft start ahead alcoa earning
271,HOLX,vincent mao
272,HOLX,stock future point slightly lower open ahead start fourth quarter earning season
273,HOLX,nasdaq future lose point vs fair value future slip point dow future drop point
274,HOLX,aluminum giant alcoa aa kick corporate report card season close worsening recession analyst expect dow component post loss cent share sale be see fall
275,HOLX,last week alcoa say slash job labor force deutsche bank cut stock sell buy share fall pre market
276,HOLX,indian outsourcer wipro wit tumble pre open world bank bar dealing wipro business unit
277,HOLX,front abbott laboratory announce plan buy advanced medical optic eye deal value include debt abbott raise earning outlook share vs view advanced medical share rocket pre market
278,HOLX,aladdin knowledge system aldn agree be buy consortium investor lead private equity firm vector capital aladdin shot pre market
279,HOLX,meanwhile investor still await official word regard deal citigroup morgan stanley ms combine brokerage unit citi share shed pre market morgan gain
280,HOLX,elsewhere crude oil drop barrel
281,HOLX,economic report be due today key item week include retail sale wed producer price thur philly fed thur consumer price fri update main index continue monday major index fumble open bell worsen day progressed close session lows nyse composite drop nasdaq breach respective day move average dow pierce day line friday lose citigroup be biggest loser blue chip index gap tumble heavy trade analyst concern just much more money struggle bank need offset news continue talk regard sale barney brokerage unit morgan stanley ms volume rise nyse fall nasdaq decliner beat advancer nyse nasdaq once again gain dwindle several recent breakout aecom technology acm shed heavy volume close buy point government contractor have now give gain dec then sxc health solution sxci drop nearly twice average trade provider pharmacy benefit management service fall winning big contract sxc finished day move average buy point life partner holding lphi fall brisk trade company deal life settlement contract report earning tuesday profit be slate rise cent share upside apollo group apol add nearly active turnover school operator earning growth accelerate recent quarters update main index log weak session juan carlos main index continue monday nasdaq slide nyse composite dow close bell volume rise nyse give dow nyse composite yet distribution day trading slow nasdaq accord early reading energy sector faltered crude price tumble again financial also sputter analyst warn bank america bac post loss again cut dividend bofa share skid citigroup plunge worry performance update volume gain index sniff new lowsby alan elliottfal financial issue overtake slide energy sector stock index carry deeper loss final hour trading nyse composite stab loss financial index drag vs drop energy index nasdaq composite tumble sag dow slump nyse volume continue strengthen nasdaq volume hold friday average level tumble gap gain advanced medical optic eye medical product heavyweight abbot laboratory say acquire cataract related product maker medical software maker cerner cern jump heavy trading put share back day move average stock try build way month consolidation masimo masi haul gain better double average volume maker patient monitoring equipment fall prior session remain deep month correction nymex show crude future trading lower barrel ice future exchange show february brent crude london edge cent lower barrel analyst be report supply glut nymex pricing hub cush okla do not reflect global supply demand balance update stock remain lower volume mixedby patrick cainstock sprang back session lows remain lower dow be nasdaq nyse be volume be higher nyse lower nasdaq martin marietta mlm seller rock gravel other construction supply fall analyst downgrade stock sell neutral company earning last quarters have decline stock recently start rise president elect barack obama plan improve infrastructure fuel business coca cola femsa kof drop bottler coca cola slice day move average begin last week stock be more upside thinly trade american italian pasta aipc gain spaghettus stock jump last week then fall hard only recover squeak gain week ensign group ensg nursing home assist live home operator be break even diving stock find support day move average update stock bounce back midday tradeby vincent maoafter extend loss major stock index try rebound midday monday nyse composite trim deficit nasdaq lose dow fall milder citigroup alcoa aa bank america bac be biggest percentage loser blue chip index turnover be again tracking mixed nyse volume higher nasdaq lower celgene celg fall guide earning sale view exclude item biotech expect full year profit range share vs analyst estimate revenue be peg vs view tower group twgp drop brisk volume extend friday decline stock have give back most gain dec cup handle southwestern energy swn lose be upgrade standard poor raise oil gas producer hold sell cite positive development fayetteville shale operation update stock hit new session lowsby vincent maocomeback effort faltered monday halftime send major index new intraday lows nyse composite tumble drag oil related issue crude oil drop barrel nasdaq pierce day move average drop meanwhile lose dow volume be tracking bit higher nyse lower nasdaq decliner beat advancer nyse slightly less nasdaq cubist pharmaceutical cbst gap day move average drop report sale view drug maker say full year sale come vs analyst estimate aecom technology acm drop continue give back gain december government contractor now sit past buy point have be nearly upside mover heavy volume be few aaron rent rnt rise erased bulk friday loss furniture appliance rental firm enter ibd week update index lows hold soft outlook alan elliotta ripple concern weaken consumer demand run world market monday drive stock commodity lower asia europe market index hold just lows weak trading action nyse composite dig loss heavily weight energy index lead downside sank nasdaq composite dow shed volume remain sharply lower nasdaq slightly nyse vs friday average trading nyse average volume nasdaq february crude contract slip barrel london brent crude shed hold barrel analyst expect wider divergence next several week crude brent crude european benchmark due unusually high stockpile particularly weak demand cush okla nymex pricing hub light sweet crude most upside stock post only modest gain research publish group ihs ihs eke private college operator apollo group apol nudge gain medical device maker thoratec thor grab advance hologic holx power gain heavy trading maker medical imaging system lower revenue estimate raise ep guidance analyst view moved earn stock upgrade hold buy jeffery co hologic remain deep yearlong consolidation downside footwear maker decker outdoor deck dive big trade fall day move average move put dent stock effort build way month consolidation overseas market asia trade generally lower shanghai composite edge modest hong kong hang seng index tumble close week low tokyo nikkei japan be close monday holiday stock moved decisively lower europe commodity pull back sharply ftse london dip frankfurt dax take loss cac index paris retract update stock open lower mixed tradeby vincent maostock open lower monday try rebound quickly get shot nyse composite breach day move average fall respectively dow slip further south day line decline nasdaq also lose remain day move average volume be tracking sharply higher nyse vastly lower nasdaq landry restaurant lry gap plunge cancel plan go private operator rainforest cafe saltgrass steak house chain instead pursue refinancing senior debt kennametal kmt gap shed announce round layoff lower profit outlook maker engineer component cut job next few month also cut fiscal earning guidance range cent share prior range cent cent harley davidson hog gap tumble goldman sachs cut motorcycle manufacturer sell neutral goldman cite potential downside impact luxury motorcycle market update stock poise soft start ahead alcoa earningsby vincent maostock future point slightly lower open ahead start fourth quarter earning season nasdaq future lose point vs fair value future slip point dow future drop point aluminum giant alcoa aa kick corporate report card season close worsening recession analyst expect dow component post loss cent share sale be see fall last week alcoa say slash job labor force deutsche bank cut stock sell buy share fall pre market indian outsourcer wipro wit tumble pre open world bank bar dealing wipro business unit front abbott laboratory announce plan buy advanced medical optic eye deal value include debt abbott raise earning outlook share vs view advanced medical share rocket pre market aladdin knowledge system aldn agree be buy consortium investor lead private equity firm vector capital aladdin shot pre market meanwhile investor still await official word regard deal citigroup morgan stanley ms combine brokerage unit citi share shed pre market morgan gain elsewhere crude oil drop barrel economic report be due today key item week include retail sale wed producer price thur philly fed thur consumer price fri
282,HOLX,update oil commodity topple dollar firm electronic retailer best buy bby slash earning outlook ill omen holiday shopping season treasury secretary henry paulson say government didn plan make purchase illiquid mortgage backed asset index respond nose diving close session lows
283,HOLX,nyse composite scour loss nasdaq composite dig dow drag decline
284,HOLX,nyse energy index lead decline financial slip amazon com amzn drop pull nasdaq dow citigroup american express axp bank america bac be first canon fire
285,HOLX,preliminary datum show volume well tuesday strong level nyse higher nasdaq marked second distribution day row major index make dow apiece nyse nasdaq composite nasdaq end just shy undercut oct low strength decline number distribution day be enough current rally send market officially back correction
286,HOLX,mean put tape buy button take close look own lock gain cut loss early give market time shake decide want go next
287,HOLX,stock decliner outpunch advance issue nyse nasdaq not industry group track ibd gain ground day very unusual gem miner steel producer coal solar energy play see deepest loss
288,HOLX,loneliest stock world be nordic american tanker shipping nat close crude oil tanker fleet operator be back week move average third week gain still face resistance week line attempt climb month correction
289,HOLX,downside solar maker take pound ja solar jaso miss earning consensus view receive downgrade standard poor ja solar slip cent
290,HOLX,more harrowing first solar fslr shed energy conversion device ener gap plunge stock be close oct low sunpower spwr drop ldk solar ldk surrender
291,HOLX,thursday morning initial jobless claim trade deficit datum be tap broader slate economic datum include retail sale natural gas inventory consumer sentiment number be due friday
292,HOLX,update slide continue late trading
293,HOLX,vincent mao
294,HOLX,major stock index hover fresh session lows late wednesday pace third straight day
295,HOLX,edt nyse composite be dow nasdaq tumble come point oct trough
296,HOLX,volume continue track higher board pace have slow decliner swamp advancer nearly nyse more nasdaq
297,HOLX,crude settle barrel gold close ounce
298,HOLX,morgan stanley ms drop unveil job cut recently converted bank hold firm plan cut institutional security staff asset manager work force
299,HOLX,rival goldman sachs gs have announce own round job cut slide ladenburg thalmann cut price target
300,HOLX,citigroup fall single digit territory erased early gain lose year low
301,HOLX,meanwhile google goog fall internet giant dip level first time year
302,HOLX,ibd component american public education apei give ahead earning report today close online school be slate earn cent share
303,HOLX,update stock bounce back midday trade
304,HOLX,vincent mao
305,HOLX,stock stumble new session lows treasury secretary henry paulson say trouble asset not be purchase originally plan index have rebound
306,HOLX,nyse composite be session low be nasdaq dow
307,HOLX,turnover be again tracking sharply higher exchange decliner trounce advancer nearly nyse nasdaq
308,HOLX,crude oil fall barrel lowest february
309,HOLX,best buy bby profit warning weigh tech sector
310,HOLX,apple aapl lose trade sixth straight day loss
311,HOLX,hewlett packard hpq fall
312,HOLX,synaptic syna gap shed active trading slice stock day move average company make control interface electronic device
313,HOLX,solar issue take heat cnbc jim cramer tout too expensive light fall oil price
314,HOLX,first solar fslr tumble brisk volume
315,HOLX,energy conversion device ener gap plunge stock be close oct low
316,HOLX,economic worry also hit airline delta dal continental cal dive respectively
317,HOLX,update index commodity dollar mixed paulson offer prognosis stock continue drill lower treasury secretary henry paulson argue expand use federal financial relief fund underscored need prop open channel consumer credit
318,HOLX,nyse composite have slip dow slump nasdaq composite limp loss
319,HOLX,dow american express axp unite technology utx hewlett packard hpq fall hardest general motor gm citigroup be only dow component gain ground
320,HOLX,trading volume continue pick tracking higher nyse nasdaq vs tuesday trading level
321,HOLX,paulson say economy financial banking system be stronger more stable just few week
322,HOLX,propose expand use trouble asset relief program tarp fund make clear market turmoil not abate biggest part mortgage crunch be say purchase illiquid mortgage backed asset be not effective use tarp fund
323,HOLX,treasury secretary say government sponsored entity gse primarily freddie mac fre fannie mae fnm now operate stable foot
324,HOLX,commodity moved generally lower morning crude future slumping barrel december contract dip low midmorning lowest price front month contract early feb dollar gain euro fall hard vs yen
325,HOLX,stock ameron international amn cave add monday pullback week strong gain water chemical transport pipe maker be feel bottom precipitous sell september
326,HOLX,upside hologic holx add cent swing high earlier trade diagnostic medical imaging system maker tuesday report flat earning just meet expectation better expect rise sale share be second week gain remain deep month correction
327,HOLX,nordic american tanker shipping nat throttle crude oil tanker fleet operator be back week move average third week gain still face resistance week line attempt climb month correction
328,HOLX,update stock open lower trimming loss
329,HOLX,vincent maoa lower profit outlook best buy overall worry economy send stock early wednesday ve pare loss
330,HOLX,nyse composite be dow nasdaq shed
331,HOLX,volume be tracking sharply higher nyse slightly higher nasdaq
332,HOLX,treasury secretary henry paulson be set provide update tarp financial bailout program
333,HOLX,american express axp fall year low reportedly ask government funding
334,HOLX,apple aapl slump brisk trade come pressure sixth straight session ipod maker be head test october lows
335,HOLX,quality system qsii drop near day move average software maker be biggest percentage loser ibd
336,HOLX,upside cephalon ceph rise fast trade drug maker be replace general growth property ggp cephalon be shape cup handle pattern
337,HOLX,update stock poise bad open
338,HOLX,vincent mao
339,HOLX,stock future signale lower start wednesday economic worry continue weigh
340,HOLX,nasdaq future shed point vs fair value future lose point dow future drop point
341,HOLX,treasury secretary henry paulson give update trouble asset relief program tarp more financial service firm well auto maker be ask government funding
342,HOLX,ford general motor gm rise respectively pre market grow belief get bailout fund
343,HOLX,best buy bby tumble pre market cut profit outlook cite weak consumer spending macroeconomic factor electronic retailer now expect full year earning range share prior guidance analyst expect share
344,HOLX,year retail ve never see such difficult time consumer person be make dramatic change much spend re not immune force best buy president chief operate officer brian dunn say statement
345,HOLX,upside macy rise report smaller expect loss exclude item department store retailer lose cent share third quarter vs estimate loss cent sale fall slightly view company also reaffirm full year profit outlook share vs view
346,HOLX,fellow department store operator jc penney jcp report friday analyst see earning fall nearly cent share
347,HOLX,financial sector american express axp reportedly seek fund government rescue plan late monday dow component win government approval become bank hold company join like goldman sachs gs morgan stanley ms share amex fall pre market
348,HOLX,dutch financial service giant ing group ing lose report first ever quarterly loss company lose euro third quarter hurt down euro
349,HOLX,crude oil slip cent barrel weekly energy inventory report be thursday update oil commodity topple dollar firm electronic retailer best buy bby slash earning outlook ill omen holiday shopping season treasury secretary henry paulson say government didn plan make purchase illiquid mortgage backed asset index respond nose diving close session lows nyse composite scour loss nasdaq composite dig dow drag decline nyse energy index lead decline financial slip amazon com amzn drop pull nasdaq dow citigroup american express axp bank america bac be first canon fire preliminary datum show volume well tuesday strong level nyse higher nasdaq marked second distribution day row major index make dow apiece nyse nasdaq composite nasdaq end just shy undercut oct low strength decline number distribution day be enough current rally send market officially back correction mean put tape buy button take close look own lock gain cut loss early give market time shake decide want go next stock decliner outpunch advance issue nyse nasdaq not industry group track ibd gain ground day very unusual gem miner steel producer coal solar energy play see deepest loss loneliest stock world be nordic american tanker shipping nat close crude oil tanker fleet operator be back week move average third week gain still face resistance week line attempt climb month correction downside solar maker take pound ja solar jaso miss earning consensus view receive downgrade standard poor ja solar slip cent more harrowing first solar fslr shed energy conversion device ener gap plunge stock be close oct low sunpower spwr drop ldk solar ldk surrender thursday morning initial jobless claim trade deficit datum be tap broader slate economic datum include retail sale natural gas inventory consumer sentiment number be due friday update slide continue late tradingby vincent maothe major stock index hover fresh session lows late wednesday pace third straight day edt nyse composite be dow nasdaq tumble come point oct trough volume continue track higher board pace have slow decliner swamp advancer nearly nyse more nasdaq crude settle barrel gold close ounce morgan stanley ms drop unveil job cut recently converted bank hold firm plan cut institutional security staff asset manager work force rival goldman sachs gs have announce own round job cut slide ladenburg thalmann cut price target citigroup fall single digit territory erased early gain lose year low meanwhile google goog fall internet giant dip level first time year ibd component american public education apei give ahead earning report today close online school be slate earn cent share update stock bounce back midday tradeby vincent maostock stumble new session lows treasury secretary henry paulson say trouble asset not be purchase originally plan index have rebound nyse composite be session low be nasdaq dow turnover be again tracking sharply higher exchange decliner trounce advancer nearly nyse nasdaq crude oil fall barrel lowest february best buy bby profit warning weigh tech sector apple aapl lose trade sixth straight day loss hewlett packard hpq fall synaptic syna gap shed active trading slice stock day move average company make control interface electronic device solar issue take heat cnbc jim cramer tout too expensive light fall oil price first solar fslr tumble brisk volume energy conversion device ener gap plunge stock be close oct low economic worry also hit airline delta dal continental cal dive respectively update index commodity dollar mixed paulson offer prognosis nyse composite have slip dow slump nasdaq composite limp loss dow american express axp unite technology utx hewlett packard hpq fall hardest general motor gm citigroup be only dow component gain ground trading volume continue pick tracking higher nyse nasdaq vs tuesday trading level paulson say economy financial banking system be stronger more stable just few week propose expand use trouble asset relief program tarp fund make clear market turmoil not abate biggest part mortgage crunch be say purchase illiquid mortgage backed asset be not effective use tarp fund treasury secretary say government sponsored entity gse primarily freddie mac fre fannie mae fnm now operate stable foot commodity moved generally lower morning crude future slumping barrel december contract dip low midmorning lowest price front month contract early feb dollar gain euro fall hard vs yen stock ameron international amn cave add monday pullback week strong gain water chemical transport pipe maker be feel bottom precipitous sell september upside hologic holx add cent swing high earlier trade diagnostic medical imaging system maker tuesday report flat earning just meet expectation better expect rise sale share be second week gain remain deep month correction nordic american tanker shipping nat throttle crude oil tanker fleet operator be back week move average third week gain still face resistance week line attempt climb month correction update stock open lower trimming lossesby vincent maoat nyse composite be dow nasdaq shed volume be tracking sharply higher nyse slightly higher nasdaq treasury secretary henry paulson be set provide update tarp financial bailout program american express axp fall year low reportedly ask government funding apple aapl slump brisk trade come pressure sixth straight session ipod maker be head test october lows quality system qsii drop near day move average software maker be biggest percentage loser ibd upside cephalon ceph rise fast trade drug maker be replace general growth property ggp cephalon be shape cup handle pattern update stock poise bad openby vincent maostock future signale lower start wednesday economic worry continue weigh nasdaq future shed point vs fair value future lose point dow future drop point treasury secretary henry paulson give update trouble asset relief program tarp more financial service firm well auto maker be ask government funding ford general motor gm rise respectively pre market grow belief get bailout fund best buy bby tumble pre market cut profit outlook cite weak consumer spending macroeconomic factor electronic retailer now expect full year earning range share prior guidance analyst expect share year retail ve never see such difficult time consumer person be make dramatic change much spend re not immune force best buy president chief operate officer brian dunn say statement upside macy rise report smaller expect loss exclude item department store retailer lose cent share third quarter vs estimate loss cent sale fall slightly view company also reaffirm full year profit outlook share vs view fellow department store operator jc penney jcp report friday analyst see earning fall nearly cent share financial sector american express axp reportedly seek fund government rescue plan late monday dow component win government approval become bank hold company join like goldman sachs gs morgan stanley ms share amex fall pre market dutch financial service giant ing group ing lose report first ever quarterly loss company lose euro third quarter hurt down euro crude oil slip cent barrel weekly energy inventory report be thursday
350,HOLX,dec issue update research report hologic inc holx free report stock currently carry zack rank hold past month manufacturer mammography system breast examination osteoporosis assessment have be outperform industry term share price stock have gain contrast fall industry hologic deliver promising performance fourth quarter fiscal revenue earning beating zack consensus estimate be upbeat stellar performance company molecular diagnostic business unite state notably company have be gain increase market share utilization fully automate panther system have also be expand market conform testing guideline regard hologic recently announce receipt clearance fda panther fusion adv hmpv rv assay multiplexed assay run new panther fusion system be also upbeat hologic progress well internationally mainly back solid contribution molecular diagnostic business regard company have be reap benefit new leadership healthy panther placement multiple product introduction include viral load assay globally notably last report quarter marked sixth consecutive period double digit growth molecular diagnostic internationally also breast health business november company announce plan make mammography system available dutch breast cancer screening program collaboration tromp medical hologic distributor netherlands also strong cash position buoy optimism flip side hologic operate highly competitive industry mammography related product subsystem compete global level also blood screening divestiture be expect impede company growth momentum key picksa few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report notably petm align technology myriad genetic sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have gain year time zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
351,HOLX,hologic inc holx free report have continue make series strategic development core breast health business contribute approximately company overall top line lately company announce development distribution agreement clarius mobile health portable ultrasound scanner system company integration clarius wireless ultrasound system hologic deep learn algorithms improve line breast health solution available patient however financial term agreement remain undisclosed be upbeat hologic consistent effort gain traction breast health business last week company also announce receipt clearance fda quantra breast density assessment software notably software be used hologic mammography system june hologic announce fda have labele genius mammography exam better standard mammography routine breast cancer screening woman dense breast segment company have redesign strategy continuous innovation leadership position mammography month company announce plan make mammography system available dutch breast cancer screening program collaboration tromp medical hologic distributor netherlands line start hologic new dimension mammography system be install mobile stationary screening facility netherlands notably roughly woman country be invite screening year program september hologic announce commercial launch dimension mammography system europe notably conjunction enhance image quality radiologist system provide improve technologist moreover aim provide more comfortable mammography experience low dose option company be upbeat latest addition suite breast cancer screening diagnostic interventional solution breast health business august hologic announce commercial launch brevera breast biopsy system corlumina imaging technology unite state be real time breast biopsy verification system enhance improve patient experience streamline entire biopsy process management be optimistic brevera contribute more april hologic acquire long time distributor breast skeletal health product medicor distributor cover sale germany austria switzerland give direct access customer have full control commercial strategy moreover acquisition have start contribute top line context company witness increase international sale fiscal courtesy medicor buyout datum provide market market breast imaging market be expect reach worth cagr however more search reveal global breast biopsy market be set see cagr period research market datum publish business wire share price hologic have be gain investor confidence consistently positive result past month stock have gain outperform broader industry company have also outperformed gain market zack rank key pickshologic carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report myriad genetic inc mygn free report luminex corp lmnx free report petm myriad sport zack rank strong buy luminex carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year myriad genetic have long term expect earning growth rate stock have gain last month luminex have long term expect earning growth rate stock have rally last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
352,HOLX,hologic inc holx free report announce receipt fda clearance quantra breast density assessment software software help clinician provide woman consistent breast density assessment routine breast cancer screening understand distribution texture breast tissue better way quantra software analyze mammography image deliver patient specific breast density assessment clinician physician now provide unbiased breast density assessment rule possibility visual subjectivity quantra software be available use hologic mammography system include new dimension mammography system notably software leverage company flagship hologic cenova server minimal technical spec platform notably hologic cenova quantra product be only available hologic mammography system breast health segment get latest regulatory progress be likely enhance hologic breast health segment notably revenue breast health segment net revenue increase year year basis cer last report fourth quarter revenue unite state slip international revenue however climb year year cer hologic be consistently try improve breast health business line company recently announce development distribution agreement clarius mobile health portable ultrasound scanner system also hologic announce commercial availability smartcurve breast stabilization system have be clinically proven deliver more comfortable mammogram compromise image quality dose market trend buoy optimismper report dpi research medium breast cancer screening market unite state be expect reach value roughly moreover article breastcancer org approximately new case invasive breast cancer woman be likely be diagnosed unite state project new case invasive breast cancer year well also report gbi research global breast cancer treatment market reach value cagr thus company clearly have bountiful prospect market share shine brightover past month company share price have outperformed broader industry stock have gain higher broader industry company have also outperformed gain market bottomlinewe believe agee population rise awareness expenditure healthcare continue drive growth breast cancer screening market not just america grow demand breast imaging asian country technological development breast cancer detection be expect open opportunity market player other hand high installation cost breast imaging system side effect radiation exposure error breast cancer screening diagnosis be impede global breast imaging market market be dominate well establish player quest diagnostic be most prominent quest diagnostic quest vantage service help genetic variant related hereditary risk type cancer include breast colorectal pancreatic renal zack rank key pickshologic carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report myriad genetic inc mygn free report luminex corp lmnx free report petm myriad sport zack rank strong buy luminex carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year myriad genetic have long term expect earning growth rate stock have gain last month luminex have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
353,HOLX,hologic inc holx free report report third quarter fiscal adjust earning share ep cent year year however adjust ep beat zack consensus estimate penny remain upper end company guidance cent strong top line growth lead better expect ep increase report quarter report basis company record net income cent share reflect year year decline respectively revenue detailrevenue gross quarter year year top line also exceed zack consensus estimate company own estimation constant exchange rate cer revenue growth be solid growth hologic molecular diagnostic gyn surgical business segment drive upside top line hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc revenue grow year year exclude blood screening medical aesthetic revenue rise other hand international revenue be cer banking increase revenue breast health gyn surgical product exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer second quarter segment molecular diagnostic revenue increase cer be primarily drive increase market share utilization fully automate panther system market expansion conform testing guideline internationally result be strong acquire benefit new leadership healthy panther placement multiple new product introduction include viral load assay cytology perinatal revenue also show decline cer revenue breast health segment inched cer revenue decline reduce incremental placement gantry international revenue however climb year year revenue gyn surgical business be cer medical aesthetic business quarter report revenue total revenue revenue skeletal health accounting rest drop cer operational updatein fiscal third quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due product geographic revenue mix divestiture blood screening business full quarter revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit fiscal third quarter cash cash equivalent considerably report end second quarter total long term debt be end fiscal third quarter compare end precede quarter year date operate cash outflow be compare cash inflow same period last year fiscal guidancehologic reduce revenue guidance fiscal company currently expect revenue range earlier band new outlook reflect annualize growth previously be current zack consensus estimate remain company provide guidance management have however raise lower end earlier provide adjust ep outlook fiscal hologic currently project adjust ep range previous fiscal reflect annualize growth current zack consensus estimate adjust ep be peg fall just upper end guide range fourth quarter fiscal hologic expect revenue represent annualize growth current zack consensus estimate fourth quarter revenue be close upper end project range adjust ep be project cent annualize decline current zack consensus estimate fourth quarter adjust ep be peg cent company guidance takehologic post better expect third quarter fiscal result term earning revenue company strong cash position be encourage factor however be disappoint decrease revenue company diagnostic segment blood screening divestiture be expect mar company growth momentum day ahead overall company reduce revenue guidance fiscal lower investor confidence stock zack rank other key pickshologic currently have zack rank sell medical stock worth consider be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report stock sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have expect long term earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have surge roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
354,HOLX,second quarter earning season have be quite impressive so far member cohort have report result latest earning preview second quarter earning whole be expect rise year year growth revenue medical broader sector zack sector be expect record earning growth quarter jul member sector post impressive earning revenue beat average respectively majority bigwig yet report result next week be crucial decide quarter turn be real game changer sector end quarter sector be anticipate witness earning growth back revenue hike medtech face political political gridlock pullback affordable care act obamacare have be make headline medtech space long such political conundrum capitol hill market watcher keep tab medtech space fraternity worry final trump care plan include medtech tax repeal agenda meanwhile old template plan promise eradicate infamous medical device tax cadillac tax excise tax high cost healthcare plan be not bad deal such hullabaloo question emerge be medical technology player stand gain lose earning season let take look major medical technology bigwig be expect release earning result aug cardinal health inc cah free report dublin base global player healthcare service product space be set report fourth quarter fiscal result bell company report adjust earning share last report quarter beat zack consensus estimate increase year year basis stock have deliver positive earning surprise past quarters average cardinal health be banking acquisition strategic buyout joint venture supply agreement drive growth furthermore growth new exist customer count be likely boost earning management cardinal health be bullish significant cash generation fourth quarter furthermore company cordis business be expect generate accretive return quarter read more cardinal health pull surprise earning model do not conclusively predict beat company give combination zack rank hold earning esp be model stock need have positive earning esp zack rank strong buy buy beat earning simultaneously caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision cardinal health inc price consensus ep surprise cardinal health inc price consensus ep surprise cardinal health inc quotehologic inc holx free report headquarter bedford hologic develop manufacture supply diagnostic medical imaging system surgical product cater healthcare need woman company be slate report third quarter fiscal result close bell last quarter company deliver positive earning surprise notably hologic earning surpass zack consensus estimate past quarters average beat overall third quarter fiscal hologic expect revenue compare prior guidance current zack consensus estimate third quarter revenue be company project range adjust ep be project cent high end previous cent range current zack consensus estimate third quarter adjust ep be peg cent company guide range read more offing hologic earning model do not conclusively predict earning beat company give combination zack rank earning esp uncover best stock buy sell re report earning esp filter hologic inc price ep surprise hologic inc price ep surprise hologic inc quotemasimo corporation masi free report irvine base masimo develop manufacture market family invasive monitoring system company be slate release second quarter result market close last quarter masimo report adjust earning cent share surpass zack consensus estimate cent revenue improve year quarter figure also steer past zack consensus estimate masimo face fierce competition oem distributor medical device bigwig mar top line sluggish hospital capital spending environment be overhang intensify competition peer overdependence third party provider customer concentration risk be major concern model do not conclusively predict beat company give combination zack rank earning esp masimo corporation price ep surprise masimo corporation price ep surprise masimo corporation quotewright medical group wmgi free report base amsterdam netherlands medical group be orthopedic medical device company specialize extremity biologic product company be schedule announce second quarter earning result bell medical report adjust loss cent share first quarter wider zack consensus estimate loss cent however loss narrow cent year year basis net sale first quarter totale be consensus mark pricing pressure continue trouble medical increase cost related product launch re build infrastructure be expect put margin pressure problem associate distributor raise concern well model do not predict earning beat company second quarter be stock have unfavorable combination zack rank earning esp medical group price ep surprise medical group price ep surprise medical group quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
355,HOLX,hologic inc holx free report be slate report third quarter fiscal financial result aug close bell last quarter company deliver positive earning surprise notably hologic earning surpass zack consensus estimate past quarters average beat let see thing be shape prior announcement factor playhologic witness lackluster performance diagnostic segment last report quarter poor cytology perinatal sale particularly longer cervical cancer screening guideline interval be play spoilsport here issue still factor company performance expect segment continue perform dull upcoming quarter be also worry fact hologic blood screening divestiture be expect impede company growth momentum day ahead expect get reflect company financial performance yet be report quarter hologic have face several challenge owing unfavorable foreign currency impact have be affect company overall performance past few quarters foreign exchange headwind be expect result reduction escalate operate expense intense competition particularly tomosynthesis market continue be concern hologic quite time now company witness several challenge such restrict capital spending environment economic uncertainty europe slower sale cycle increase pricing pressure expect problem linger upcoming quarters well company get significant synergy benefit third quarter integration cynosure inc medical aesthetic system technology company hologic acquire mar mention fda have recently grant expand clearance cynosure invasive body contour product sculpture treat back inner outer thigh come product launch third quarter company receive european ce mark new panther fusion system panther fusion assay flu respiratory testing also company announce fda approval itsgenius mammography exam several other product launch also boost upcoming quarterly result overall third quarter fiscal hologic expect revenue compare prior guidance current zack consensus estimate third quarter revenue be company expectation adjust ep be project cent cent high end previous cent cent range current zack consensus estimate third quarter adjust ep be peg cent company guidance earning whispersour proven model do not conclusively show hologic be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp hologic have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank hologic have zack rank note caution sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company want consider model show have right combination element come earning beat quarter dextera surgical inc have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here idexx laboratory inc idxx free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
356,HOLX,hologic inc holx free report recently announce receipt health canada approval new panther fusion system panther fusion assay respiratory virus infection panther fusion respiratory assay include panther fusion flu rsv panther fusion paraflu panther fusion adv hmpv rv test further pcr polymerase chain reaction base assay offer highly advanced approach syndromic testing ability run assay single patient specimen base patient requirement accord company new assay combine aptima transcription mediate amplification tma assay enable panther fusion system only instrument combine tma real time tma real time pcr full sample result automation notably panther fusion module be lab upgrade original panther instrument apart panther platform exist benefit new system add flexibility pcr proven performance tma used panther system further result new system certain additional benefit increase flexibility enhance time cost efficiency also be obtain laboratory company regulatory approval be also obtain new assay flu respiratory infection extend variety diagnostic test capable be run hologic system market prospectsper cision molecular diagnostic market be project reach cagr consider huge market potential believe company latest development be quite strategic hologic be consistently try expand diagnostic segment generate total revenue last report quarter face year year decline segment molecular diagnostic revenue increase constant exchange rate stock performance solidover past month hologic have outperformed industry stock have gain decline industry recent regulatory approval glancerecently hologic announce receipt medical device license issue health canada distribute cynosure invasive body contour product sculpsure treat back inner outer thigh submental area moreover company announce fda have grant premarket approval pma thinprep integrate imager make automate imaging pap test broadly available laboratory cytologist unite state april company clarity hd high resolution imaging intelligent imaging technology have also receive pma approval fda be now available dimension breast tomosynthesis system again january hologic announce fda have grant pma approval aptima hbv quant assay quantitation hepatitis viral load fully automate panther system cynosure division also announce launch tempsure envi same month be fda clear advanced radiofrequency device minimize facial fine line wrinkle tighten skin soft tissue coagulation improve appearance cellulite believe recent spree regulatory approval company array product be go boost share price further zack rank key pickshologic currently carry zack rank hold few better rank stock broader medical sector be illumina inc ilmn free report amedisys inc am free report walgreen boot alliance inc wba free report illumina amedisys sport zack rank strong buy walgreen boot carry zack rank buy see complete list today zack rank stock here illumina expect long term earning growth amedisys have expect long term earning growth rate walgreen boot have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
357,HOLX,have be month last earning report hologic inc holx free report share have lose time frame recent negative trend continue lead next earning release be holx due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningshologic report second quarter fiscal adjust earning share ep cent year year line low end company cent guidance adjust ep be also par zack consensus estimate report basis company record net loss share net income second quarter fiscal notably report figure include cash impairment charge goodwill process research development associate hologic cynosure business revenue detailrevenue gross quarter year year constant exchange rate cer top line surpass zack consensus estimate company guidance solid contribution breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline marginally international revenue be cer strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer second quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive new product revenue continue solid uptake aptima woman health product cytology perinatal revenue also show improvement cer revenue breast health segment inched cer revenue growth unite state be roughly flat report quarter upside be lead higher service new product revenue international revenue however climb year year mark third consecutive quarter growth exceed revenue gyn surgical business be cer medical aesthetic business quarter report revenue reflect total revenue revenue skeletal health accounting rest increase cer operational updatein fiscal second quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business geographic mix revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit second quarter fiscal cash cash equivalent compare end first quarter fiscal total long term debt be end report quarter compare first quarter fiscal quarter company generate operate cash flow compare year guidancehologic have update fiscal financial guidance company currently expect adjust revenue compare previous range company expect revenue grow range compare previously provide range cer zack consensus estimate revenue be guide range adjust ep guidance remain unchanged call growth zack consensus estimate adjust ep be peg guide range third quarter fiscal hologic expect adjust revenue represent annualize decline cer zack consensus estimate revenue be peg project range adjust ep be estimate cent reflect annualize growth zack consensus estimate third quarter adjust ep be pin cent company guidance have estimate be move then past month investor have witness downward trend fresh estimate have be revision lower current quarter hologic inc price consensus hologic inc price consensus hologic inc quotevgm scoresat time holx have subpar growth score grade same score momentum front stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be suitable solely value base style score outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably holx have zack rank hold expect line return stock next few month
358,HOLX,hologic inc holx free report be slate report first quarter fiscal financial result feb close bell last quarter company deliver positive earning surprise notably hologic earning surpass zack consensus estimate past quarters average beat let see thing be shape prior announcement key catalystper company jan release preliminary revenue performance first quarter fiscal be expect report total revenue year year constant exchange rate cer preliminary prediction edge past company guide range be report quarter zack consensus estimate same period be peg company preliminary number hologic inc price ep surprise hologic inc price ep surprise hologic inc quote diagnostic company expect report revenue year report figure zack consensus estimate remain year number year year decline be attribute estimate loss be incur divest blood screening franchise also company witness dull sale performance cytology perinatal product recent past international growth fourth quarter cytology revenue number decline primarily dismal sale performance unite state however hologic be expect see stellar performance molecular diagnostic major subsegment diagnostic unite state company be expect gain increase market share utilization fully automate panther system market expansion conform testing guideline earlier hologic state have ship panther diagnostic customer unite state end company note actually ship slightly more panther system period do year turn illustrate company sturdy competitive edge molecular diagnostic space notably hologic have recently receive fda approval market aptimaherpe simplex virus molecular assay panther system company believe nod draw more customer apart broaden panther woman health menu last quarter molecular diagnostic result be robust internationally markingthe sixth consecutive quarter double digit growth upside wascourtesy benefit new leadership healthy panther placement multiple product introduction development further boost molecular diagnostic revenue be report quarter zack consensus estimate molecular diagnostic revenue reflect increase year quarter here be few other factor influence hologic fourth quarter result hologic be hopeful sustain solid earning trend back gain gyn surgical segment strong global sale myosure have be drive top line segment give huge market potential myosure expect company maintain bullish trend regard note launch myosure manual device have help widening company gynecologic zack consensus estimate gyn surgical revenue first quarter fiscal remain line prior year tally also zack consensus estimate myosure revenue represent rise year period first quarter adjust ep be project cent reflect annualize decline zack consensus estimate metric same period be peg cent guide range flip side hologic have face challenge related unfavorable foreign currency movement past few quarters escalate operate expense intense competition particularly tomosynthesis market continue raise concern quantitative model predict proven model do not conclusively show hologic be likely beat estimate quarter be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp hologic have earning esp uncover best stock buy sell re report earning esp filter zack rank hologic carry zack rank sell stock worth lookhere be few medical stock worth consider right combination element beat earning time amphastar pharmaceutical inc amph free report have earning esp zack rank anthera pharmaceutical inc anth free report have earning esp zack rank fibrocell science inc fcsc free report have earning esp be zack rank player see complete list today zack rank stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
359,HOLX,have be more month last earning report hologic inc holx free report share have add time frame outperform market recent positive trend continue lead stock next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningshologic report fourth quarter fiscal adjust earning share ep cent year year however adjust ep beat zack consensus estimate penny remain upper end company guidance cent report basis company record earning cent share reflect year year decline revenue detailrevenue gross quarter year year constant exchange rate cer top line also exceed zack consensus estimate company own estimation solid double digit growth hologic molecular diagnostic international business drive upside top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue rise other hand international revenue be cer banking strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer fourth quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive increase market share utilization fully automate panther system notably end hologic have ship panther diagnostic customer worldwide quarter marked sixth consecutive period double digit growth molecular diagnostic internationally cytology perinatal revenue also show decline cer revenue breast health segment inched cer revenue unite state slip report quarter change product mix be partially offset increase service new product revenue international revenue however climb year year cer revenue gyn surgical business be cer medical aesthetic business quarter report revenue determine total revenue revenue skeletal health accounting rest increase cer operational updatein fiscal fourth quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit fiscal cash cash equivalent marginally report end fiscal total long term debt be end fiscal compare end last fiscal full year operate cash flow be compare year cash flow guidancehologic have provide fiscal financial guidance company currently expect adjust revenue grow range cer current zack consensus estimate stand guide rangeadjust ep be expect grow current zack consensus estimate adjust ep be peg fall just upper end guide range first quarter fiscal hologic expect adjust revenue represent annualize growth cer current zack consensus estimate revenue be peg ahead project range adjust ep be project cent reflect annualize decline current zack consensus estimate first quarter adjust ep be peg cent company guidance have estimate be move then analyst be quiet past month none issue earning estimate revision hologic inc price consensus hologic inc price consensus hologic inc quotevgm scoresat time hologic stock have poor growth score grade same score momentum front however stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be suitable solely value base style score stock have zack rank hold be expect inline return stock next few month
360,HOLX,hologic inc holx free report announce receipt clearance fda panther fusion adv hmpv rv assay be multiplex assay run new panther fusion system detect adenovirus human metapneumovirus rhinovirus company initial set modular assay respiratory viruse be complete fda nod latest panther fusion assay offer new age approach syndromic respiratory testing prolific ability run assay single patient specimen assay complement other fda approve assay namely panther fusion flu rsv panther fusion paraflu variety panther fusion module be lab upgrade original panther instrument apart panther platform exist benefit new system add flexibility pcr polymerase chain reaction proven performance transcription mediate amplification tma used panther system market prospectsper cision molecular diagnostic market be project reach worth cagr consider huge market potential believe company latest development be quite strategic hologic be consistently try expand diagnostic segment generate total revenue last report fiscal fourth quarter face year year decline segment molecular diagnostic revenue increase cer notably end hologic have ship panther diagnostic customer worldwide stock performance solidover past month hologic have outperformed broader industry stock have gain decline broader industry recent regulatory approval glancerecently company announce receipt fda clearance quantra breast density assessment software october hologic announce receipt clearance fda panther fusion paraflu assay also company announce fda approval panther fusion flu rsv assay run new panther fusion system company also receive fda approval commercial launch aptima herpes simplex virus hsv molecular assay fully automate panther system june also receive fda expand clearance sculpsure product june believe recent spree regulatory approval company array product boost share price further zack rank key pickshologic carry zack rank hold few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report sporting zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have surge roughly year align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have soar year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
361,HOLX,hologic inc holx free report report second quarter fiscal adjust earning share ep cent year year line low end company cent guidance adjust ep be also par zack consensus estimate report basis company record net loss share net income second quarter fiscal notably report figure include cash impairment charge goodwill process research development associate hologic cynosure business revenue detailrevenue gross quarter year year constant exchange rate cer top line surpass zack consensus estimate company guidance solid contribution breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline marginally international revenue be cer strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesegment detailrevenue diagnostic segment total revenue decline year year cer second quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive new product revenue continue solid uptake aptima woman health product cytology perinatal revenue also show improvement cer revenue breast health segment inched cer revenue growth unite state be roughly flat report quarter upside be lead higher service new product revenue international revenue however climb year year mark third consecutive quarter growth exceed revenue gyn surgical business be cer medical aesthetic business quarter report revenue reflect total revenue revenue skeletal health accounting rest increase cer operational updatein fiscal second quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business geographic mix revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit second quarter fiscal cash cash equivalent compare end first quarter fiscal total long term debt be end report quarter compare first quarter fiscal quarter company generate operate cash flow compare year guidancehologic have update fiscal financial guidance company currently expect adjust revenue compare previous range company expect revenue grow range compare previously provide range cer zack consensus estimate revenue be guide range adjust ep guidance remain unchanged call growth zack consensus estimate adjust ep be peg guide range third quarter fiscal hologic expect adjust revenue represent annualize decline cer zack consensus estimate revenue be peg project range adjust ep be estimate cent reflect annualize growth zack consensus estimate third quarter adjust ep be pin cent company guidance takehologic exit second quarter fiscal mixed note growth geographical region buoy optimism however be disappoint decline revenue diagnostic segment blood screening divestiture be also likely impede growth company further company lower revenue guidance fiscal reduce sale expectation cynosure business raise concern zack rank key pickshologic carry zack rank sell few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep steering past zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
362,HOLX,medical product industry have lately be highly profitable investment space courtesy agee populace change market dynamic robotic surgery big datum application upbeat consumer sentiment abolition medical device taxe innovation higher consolidation various report claim be largest medical device market world rake more revenue view trend medical product industry have return year date stark contrast loss meanwhile first quarter earning season have also take center stage already member elite index have report financial number so far latest earning preview performance index participant indicate increase total earning higher revenue beat ratio have be impressive well company surpass bottom line expectation outperform top line medical sector zack sector have deliver strong performance sector be expect rise higher revenue give trend be rather interesting see major medical product company be place ahead report cycle let take look major company be set release result cerner corporation cern free report first quarter release be likely show strong performance system sale segment management upside be attribute growth license software however improvement other segment also lead better result read more higher system sale drive cerner earning lately company witness slew development electronic health record ehr platform cerner millenium ehr have be choose be implement new cerner integrate behavioral health deployment model texas base menninger clinic first quarter zack consensus estimate earning be peg cent same revenue be reflect year year growth cerner have earning esp zack rank hold zack quantitative model stock advantageous combination solid zack rank strong buy buy positive earning esphave higher chance beating estimate uncover best stock buy sell re report earning esp filter notably caution stock zack rank sell strong sell go earning announcement especially company be see negative estimate revision cerner corporation price consensus cerner corporation price consensus cerner corporation corporation abc free report second quarter fiscal result be expect show steady growth pharmaceutical distribution segment significant contributor revenue strong organic growth rate pharmaceutical market improve patient access medical care improve economic condition population demographic introduction new innovative drug like hepatitis consistent good brand pricing environment drive growth quarter be report read more store earning zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg indicate increase year year have earning esp zack rank see complete list today zack rank stock here corporation price consensus corporation price consensus corporation quotehologic inc holx free report come second quarter fiscal result company be expect witness stellar performance molecular diagnostic unit unite state company be likely gain increase market share well utilization fully automate panther system market expansion conform testing guideline global growth molecular diagnostic be attribute panther system hologic fully automate molecular diagnostic instrument frequent utilization aptima woman health assay read more hologic diagnostic growth recur earning quarter be report zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg cent share indicate increase year year hologic have earning esp zack rank hologic inc price consensus hologic inc price consensus hologic inc quotemasimo corporation masi free report first quarter result be expect register strong growth expand product portfolio wider adoption invasive patient monitoring technology product revenue be expect witness impressive growth overseas market new product include nomoline capnography sedline brain function monitoring organ oximetry be expect contribute result quarter be report zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg cent share indicate increase year year masimo have earning esp zack rank masimo corporation price consensus masimo corporation price consensus masimo corporation quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
363,HOLX,hologic inc holx free report report fourth quarter fiscal adjust earning share ep cent year year however adjust ep beat zack consensus estimate penny remain upper end company guidance cent report basis company record earning cent share reflect year year decline revenue detailrevenue gross quarter year year constant exchange rate cer top line also exceed zack consensus estimate company own estimation hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesolid double digit growth hologic molecular diagnostic international business drive upside top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue rise other hand international revenue be cer banking strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer fourth quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive increase market share utilization fully automate panther system notably end hologic have ship panther diagnostic customer worldwide quarter marked sixth consecutive period double digit growth molecular diagnostic internationally cytology perinatal revenue also show decline cer revenue breast health segment inched cer revenue unite state slip report quarter change product mix be partially offset increase service new product revenue international revenue however climb year year cer revenue gyn surgical business be cer medical aesthetic business quarter report revenue determine total revenue revenue skeletal health accounting rest increase cer operational updatein fiscal fourth quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit fiscal cash cash equivalent marginally report end fiscal total long term debt be end fiscal compare end last fiscal full year operate cash flow be compare year cash flow guidancehologic have provide fiscal financial guidance company currently expect adjust revenue grow range cer current zack consensus estimate stand guide rangeadjust ep be expect grow current zack consensus estimate adjust ep be peg fall just upper end guide range first quarter fiscal hologic expect adjust revenue represent annualize growth cer current zack consensus estimate revenue be peg ahead project range adjust ep be project cent reflect annualize decline current zack consensus estimate first quarter adjust ep be peg cent company guidance takehologic post better expect fourth quarter fiscal result term earning revenue balanced growth geographical region buoy optimism however be disappoint decrease revenue company diagnostic segment blood screening divestiture be also likely mar company growth momentum day ahead zack rank key pickshologic carry zack rank hold few better rank medical stock be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report adjust earning share cent third quarter year year company revenue quarter increase almost year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
364,HOLX,hologic inc holx free report be slate report fourth quarter fiscal financial result nov close bell last quarter company deliver positive earning surprise notably hologic earning surpass zack consensus estimate past quarters average beat be let see thing be shape prior announcement key catalystsimilar last quarter hologic be expect see stellar performance molecular diagnostic business unite state company be expect gain increase market share utilization fully automate panther system market expansion conform testing guideline notably hologic recently receive fda approval market aptimaherpe simplex virus molecular assay panther system company believe approval draw customer apart broaden panther woman health menu internationally molecular diagnostic result be strong last report quarter courtesy benefit new leadership healthy panther placement multiple product introduction include viral load assay meanwhile be upbeat company receipt european ce mark new panther fusion system panther fusion assay flu respiratory testing june company also receive ce mark aptima combo assay chlamydium trachomatis neisseria gonorrhoeae same month development boost molecular diagnostic revenue be report quarter hologic inc price ep surprise hologic inc price ep surprise hologic inc quote zack consensus estimate molecular diagnostic revenue reflect increase year quarter sequentially here be other factor influence hologic fourth quarter result hologic be hopeful sustain solid earning trend back gain gyn surgical segment strong global sale myosure have be drive top line segment give huge market potential myosure expect company maintain bullish trend zack consensus estimate gyn surgical revenue reflect increase year quarter also zack consensus estimate myosure revenue reflect increase year quarter company be also position rake significant benefit fourth quarter integration cynosure medical aesthetic system technology company be acquire hologic march fda recently grant expand clearance cynosure invasive body contour product sculpsure treat submental area approval marked sculpsure sixth clear body treatment area fourth quarter fiscal hologic expect revenue represent annualize growth current zack consensus estimate fourth quarter revenue be project range reflect increase year quarter adjust ep be project cent show annualize decline however current zack consensus estimate fourth quarter adjust ep cent reflect decline year quarter flip side hologic blood screening divestiture be expect impede company growth momentum expect get reflect company financial performance be report quarter hologic also have face challenge related unfavorable foreign currency past few quarters escalate operate expense intense competition particularly tomosynthesis market continue concern here be quantitative model predict proven model do not conclusively show hologic be likely beat earning quarter be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp hologic have earning esp uncover best stock buy sell re report earning esp filter zack rank hologic currently carry zack rank sell stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter qiagen qgen free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank penumbra inc pen free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
365,HOLX,survey report gallup analytic last month reveal adult cite healthcare wider industry medical device second major problem face country new presidential administration give current lack clarity let concentrate powerful long term tailwind medical device industry emerge market expansion merger acquisition positive demographic trend new product innovation have be drive sector impressive performance severe socio economic political instability let elaborate major long term driver medtech sector emerge market openingsit have be see even consider dull performance medical device market still hold lead position almost third world market share rise regulatory legislative uncertainty global growth have be strong industry grow pace last see financial crisis health policy debacle unite state also consider worsening economic condition europe conclude encourage global growth come mainly emerge market china india latin america other go recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india medtech market fifth largest world be currently demonstrate annual growth continue india give good competition japan germany other emerge geographical region latin america even face general economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare give huge potential region long back johnson johnson jnj free report have set manufacturing center brazil china india company medical device segment emerge market be grow time faster develop market abbott lab continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report last report first quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic remain confident long term outlook emerge market company be focuse develop new public private partnership well execute channel optimization strategy boston scientific bsx emerge market business register organic growth second quarter reflect significant increase growth business china be once again remarkable year year company be currently look forward much better performance ahead china banking recent approval synergy china major follow company colossal consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company anticipate emerge lead player point care diagnostic space path breaking mega consolidation be way medical device major becton dickinson co bdx medical surgical diagnostic patient care device provider bard inc bcr completion deal expect fourth quarter fiscal becton dickinson promise create third business segment bd interventional august fresenius medical care ag co kgaa fms sign deal acquire nxstage medical nxtm free report takeover be expect boost revenue care coordination segment fresenius medical care johnson johnson medical device arm move expand internationally recently agree acquire germany base surgical process institute specialist standardization digitalization surgical workflow operate theatre apart boston scientific acquisition switzerland base symetis sa fortify structural heart business europe also company recently close deal acquire campbell base apama medical fortify company position market other notable bid worth mention be integra lifescience recent acquisition codman neurosurgery business johnson johnson apart september cooper enter agreement teva pharmaceutical industry acquire global right business teva paragard intrauterine device iud cash transaction divestment medical device major continue offload core business line specifically focus main segment divest asset be similar one acquire merger divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market order focus portfolio deliver global strategic priority medtronic decide divest part pmr patient monitoring recovery division mitg minimally invasive therapy group business cardinal health deal value follow announcement major buyout abbott divest eyecare business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure recently sell hologic inc holx notably hologic acquire outstanding cynosure share approximately sharpen strategic focus core business ecolab ecl recently decide sell equipment care business audax private equity boston base private equity firm also medical wmgi recent divestiture large joint hip knee business be example focus former put core business development bid reduce refine portfolio repay long term debt community health system inc cyh divest rockwood health system associate asset multicare health system key pick medical product stock terumo corporation trumy free report sporting zack rank strong buy look attractive abbott neogen corporation neog free report resm inc rmd free report be also well poise zack rank buy medical instrument space be positive luminex corporation lmnx free report olympus corporation ocpny free report carry zack rank other also be optimistic thermo fisher scientific inc tmo steris plc ste free report mesa laboratory inc mlab zack rank weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring be nuvasive inc nuva free report cardiovascular system inc csii stryker corporation syk free report meridian bioscience inc vivo free report carry zack rank sell nxstage medical inc nxtm free report dextera surgical inc dxtr hold zack rank strong sell
366,HOLX,cerner corporation cern free report first quarter result be schedule release market close system sale be likely be growth driver improvement other segment also lead better result fourth quarter cerner report adjust earning share cent cent year figure also miss zack consensus estimate cent cerner have average negative earning surprise trail quarters meanwhile revenue rise year year marginally miss zack consensus estimate first quarter zack consensus estimate earning be peg cent same revenue be reflect year year growth cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quotelet dig deeper system sale focusin last report quarter segment account total revenue revenue segment totale year year management upside be attribute growth license software moreover full year system sale revenue grow margin increase first quarter zack consensus estimate segment revenue be pin year year other factor playehr prospectscerner electronic health record ehr platform have majorly trigger growth lately company witness slew development ehr platform cerner millenium ehr have be choose be implement new cerner health deployment model texas base menninger clinic cerner be also select illinois rural community care organization ircco implement cerner healtheintent accountable care organization notably healtheintent play significant role drive cerner earning last report quarter company end year healtheintent client resultantly population health booking grow revenue rise furthermore last report quarter company witness record booking growth more be attribute latest ehr deal booking come outside core millennium install base support maintenance servicein last report quarter segment account whopping total revenue revenue segment come year year basis line management expectation first quarter zack consensus estimate revenue segment be peg reflect rise year year guidance solidcerner expect first quarter revenue adjust earning share be project range cent revenue be forecast band full year adjust earning share be estimate range new business booking first quarter be expect range decline margin high debtin last report quarter operate margin come contract basis point bps year year basis downside be cause year year surge operate expense rise be drive personnel expense related revenue generate associate cash item additionally long term debt amount end quarter quantitative model do not conclusively show beat cerner earning season be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp cerner be uncover best stock buy sell re report earning esp filter earning esp filter zack rank cerner carry zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider have right combination element post beat earning season stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
367,HOLX,cardinal health inc cah free report third quarter fiscal result be schedule release market open result be likely show decline core pharmaceutical segment growth other segment be likely make partially second quarter fiscal company report adjust earning share prior year quarter also zack consensus estimate revenue come year year basis outpace consensus estimate notably cardinal health have negative average earning surprise trail quarters zack consensus estimate third quarter earning be peg reflect decline year year same revenue be pin indicate growth cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quotelet delve deeper pharmaceutical segment focusin last report quarter segment account enormous company revenue revenue segment come year year basis segment witness strong growth specialty business also gain huge number pharmaceutical distribution customer however see drop profit thank generic pharmaceutical pricing recent investment pharmaceutical platform lackluster generic program performance management growth segment be further impede expiration large mail order prime therapeutic current quarter zack consensus estimate revenue sequentially other factor playguidance liftedconsider benefit slash federal tax rate cardinal health raise fiscal outlook company expect adjust earning share continue operation compare previous range medical segmentin fiscal second quarter segment account company revenue revenue segment grow primarily drive patient recovery acquisition medical segment profit increase courtesy higher contribution new exist customer acquisition patient recovery business current quarter zack consensus estimate revenue segment be peg sequentially medical glove unitcardinal health offer robust portfolio medical glove include surgical glove exam glove clean room glove company have be lately face challenge exam glove sub segment last report quarter commodity pricing supply disruption be major draghunt section fiscal lower expectation medical segment due trouble exam glove segment raise concern quantitative model do not conclusively predict earning beat cardinal health earning season be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp cardinal health be uncover best stock buy sell re report earning esp filter zack rank cardinal health carry zack rank sell stock worth lookhere be few medical stock worth consider have right combination element post beat earning season stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
368,HOLX,becton dickinson company bdx free report popularly know bd second quarter fiscal result be schedule release market open result be likely show steady growth core bd medical segment rise revenue other segment also act driver first quarter bd report earning share beat zack consensus estimate adjust earning increase constant currency cc year year basis revenue come beating consensus estimate show rise year quarter second quarter zack consensus estimate earning be peg reflect year year growth same revenue be pin indicate growth bd deliver average positive earning surprise trail quarters becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotelet delve deeper bd medical key growth driverin last report quarter bd medical account whopping company total revenue revenue segment rise cc year year basis management include headwind approximately basis point bps dispense change furthermore add legacy bard have lead accelerate growth segment be also encourage note second quarter zack consensus estimate segment be sequentially medication procedural solution mps revenue grow first quarter second quarter zack consensus estimate be peg sequentially growth be likely be drive continue strength pre filled flush device infection prevention surgical product diabetes care revenue grow growth pen needle yet zack consensus estimate quarter be pin sequentially pharmaceutical system revenue grow first quarter zack consensus estimate second quarter be show rise sequentially revenue medication management solution mms decline zack consensus estimate be sequentially other factor playview solidbd expect fiscal revenue growth range report basis however revenue be expect grow band company expect adjust earning share range previous range current range indicate growth approximately report basis cc management expect bd medical grow life science segment be expect rise growth new bd interventional segment be anticipate acquisition divestituresbd acquisition drive strategy have be instrumental drive growth recently bd acquire bard management bd be way become biggest medical technology device company world approximately annualize revenue closure takeover lead third new business segment bd interventional bd collaborative move fresenius medical care provide sodium chloride saline customer be also worth mention last year bd announce merit medical system have sign agreement acquire certain asset company bd life sciencesrevenue bd life science totale fiscal first quarter cc year segment performance be backed strong number bioscience diagnostic system preanalytical system unit segment also see solid growth outside unite state recently bd announce pre market approval fda bd onclarity hpv assay management be likely boost bd diagnostic system segment zack consensus estimate second quarter be pin sequentially quantitative model predict earning beat bd quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp bd be uncover best stock buy sell re report earning esp filter zack rank bd carry zack rank favorable zack rank increase predictive power esp other stock worth lookhere be few other medical stock worth consider have right combination element post beat earning season stryker corp syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
369,HOLX,strengthen breast health portfolio hologic inc holx free report recently announce receipt pma approval fda clarity hd high resolution imaging intelligent imaging technology follow approval product be now available dimension breast tomosynthesis system notably conjunction enhance image quality radiologist system provide improve technologist moreover aim provide more comfortable mammography experience low dose option encouragingly note hologic have already place mammography system unite state company be optimistic recent addition suite breast cancer screening diagnostic interventional solution breast health business clarity hd high resolution imaging intelligent imaging technologiesper company clarity hd high resolution imaging technology have be develop design articulately subtle lesion fine calcification help diagnose cancer early moreover clarity hd technology combination innovative detector advanced imaging algorithm aid produce superior image regardless breast density size furthermore intelligent imaging technology combination clarity hd technology deliver exceptional overall image quality lower dose breast health unit focuswe be upbeat hologic consistent effort gain traction breast health business have contribute company overall top line growth first quarter fiscal segment record growth constant currency quarter company unique direct consumer initiative segment provide competitive edge niche space bid enhance breast health portfolio hologic recently announce worldwide collaboration deal royal philips phg lead health technology company global partnership agreement provide integrate imaging solution woman health november company announce development distribution agreement clarius mobile health portable ultrasound scanner system also announce receipt clearance fda quantra breast density assessment software later month notably software be used hologic mammography system segment company have redesign strategy continue innovation leadership position mammography also november announce plan make mammography system available dutch breast cancer screening program collaboration tromp medical hologic distributor netherlands line start hologic latest dimension mammography system be install mobile stationary screening facility netherlands market trend buoy optimismper report dpi research medium breast cancer screening market unite state be expect reach value roughly also report gbi research global breast cancer treatment market reach value cagr thus company clearly have solid prospect market share price performanceover past month hologic decline underperform industry gain believe latest fda nod help stock rebound zack rank key pickshologic carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
370,HOLX,hologic inc holx free report announce receipt clearance fda panther fusion flu rsv assay run new panther fusion system follow ce mark approval earlier year latest fda clearance be treat major breakthrough company molecular diagnostic arm panther fusion module be lab upgrade original panther instrument add flexibility pcr polymerase chain reaction proven performance transcription mediate amplification tma be used panther system panther fusion system have benefit panther platform include full sample result automation ability run multiple test single sample random access sample process continuous load stat capability moreover feature provide higher throughput panther fusion test hour fusion aptima test be also incorporate unite state panther fusion be available full system testing capability be extend attach panther fusion module exist panther system apart panther fusion flu rsv assay additional respiratory panel panther fusion paraflu assay panther fusion adv hmpv rv adenovirus human metapneumovirus rhinovirus assay be presently fda review accord company panther fusion respiratory assay offer modular approach testing ability run assay single patient specimen panther fusion assay also use ready use reagent offer day board stability panther fusion system cut hand time laboratory provide random continuous access rapid turnaround time panther fusion system be only instrument combine tma transcription mediate amplification real time tma real time pcr full sample result automation hologic be consistently try expand diagnostic segment notably segment generate total revenue last report third quarter face year year decline accord cision molecular diagnostic market be project reach worth cagr consider huge potential market believe company latest development be quite strategic past month hologicha underperform broader industry stock have lose gain broader industry zack rank key pickshologic currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term estimate earning growth rate stock gain last month idexx laboratory have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
371,HOLX,more have go last earning report hologic inc holx free report share have lose time frame underperform market recent negative trend continue lead stock next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningshologic inc report third quarter fiscal adjust earning share ep year year however adjust ep beat zack consensus estimate penny remain upper end company guidance strong top line growth lead better expect ep increase report quarter report basis company record net income share reflect year year decline respectively revenue detailrevenue gross quarter year year top line also exceed zack consensus estimate company own estimation constant exchange rate cer revenue growth be solid growth hologic molecular diagnostic gyn surgical business segment drive upside top line geographically revenue grow year year exclude blood screening medical aesthetic revenue rise other hand international revenue be cer banking increase revenue breast health gyn surgical product exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer second quarter segment molecular diagnostic revenue increase cer be primarily drive increase market share utilization fully automate panther system market expansion conform testing guideline internationally result be strong acquire benefit new leadership healthy panther placement multiple new product introduction include viral load assay cytology perinatal revenue also show decline cer revenue breast health segment inched cer revenue decline reduce incremental placement gantry international revenue however climb year year revenue gyn surgical business be cer medical aesthetic business quarter report revenue total revenue revenue skeletal health accounting rest drop cer operational updatein fiscal third quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due product geographic revenue mix divestiture blood screening business full quarter revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit fiscal third quarter cash cash equivalent considerably report end second quarter total long term debt be end fiscal third quarter compare end precede quarter year date operate cash outflow be compare cash inflow same period last year fiscal guidancehologic reduce revenue guidance fiscal company currently expect revenue range earlier band new outlook reflect annualize growth previously be current zack consensus estimate remain company provide guidance management have however raise lower end earlier provide adjust ep outlook fiscal hologic currently project adjust ep range previous fiscal reflect annualize growth current zack consensus estimate adjust ep be peg fall just upper end guide range fourth quarter fiscal hologic expect revenue represent annualize growth current zack consensus estimate fourth quarter revenue be close upper end project range adjust ep be project annualize decline current zack consensus estimate fourth quarter adjust ep be peg company guidance have estimate be move then analyst be quiet past month none issue earning estimate revision hologic inc price consensus hologic inc price consensus hologic inc quotevgm scoresat time hologic stock have poor growth score however momentum be do bit better charting somewhat similar path stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be suitable solely value base style score outlook notably stock have zack rank hold be look inline return stock next few month
372,HOLX,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put hologic inc holx free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front hologic have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend hologic current pe level put midpoint past year moreover current level stand well high stock suggest be great entry point further stock pe compare favorably zack medical sector trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point hologic have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead hologic stock term too cf ratioan often overlooked ratio still be great indicator value be price cash flow metric ratio doesn take amortization depreciation account so give more accurate picture financial health business be prefer metric valuation investor cash flow be generally less prone manipulation company management be less affected variation accounting policy different company ratio be generally apply find company stock be overpriced underpriced reference cash flow generation potential compare competitor however be not commonly used cross industry comparison average price cash flow ratio vary industry industry case hologic cf ratio be much lower zack medical instrument industry average indicate stock be quite undervalue respect broad value outlookin aggregate hologic currently have value score putt top stock cover look make hologic solid choice value investor other key metric make pretty clear too example peg ratio hologic be just level be far lower industry average peg ratio be modify pe ratio take account stock earning growth rate additionally cf ratio great indicator value come be far better industry average clearly holx be solid choice value front multiple angle stock overall hologic be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give holx zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be quite encourage current quarter have see estimate go higher past day compare lower full year estimate have see same time period have have positive impact consensus estimate current quarter consensus estimate have inched higher past month full year estimate have rise see consensus estimate trend recent price action stock chart hologic inc price consensus hologic inc price consensus hologic inc quotehowever somewhat bullish trend have likely not yet be reflect stock have just zack rank hold indicate expectation line performance term nonetheless bullish analyst sentiment indicate stock prospect term look good bottom linehologic be inspire choice value investor be hard beat incredible lineup statistic front however sluggish zack industry rank bottom more industry zack rank be hard get too excited company overall nevertheless past year industry have outperformed broader market see so value investor want broader industry factor improve further once happen stock be compelling pick look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
373,HOLX,have be month last earning report hologic inc holx free report share have lose time frame recent negative trend continue lead next earning release be holx due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent earningshologic report first quarter fiscal adjust earning share ep cent year year moreover adjust ep beat zack consensus estimate surpass company guidance cent report basis company record ep compare cent first quarter fiscal notably report figure include time tax provision net benefit courtesy tax reform revenue detailrevenue gross quarter year year constant exchange rate cer top line also exceed zack consensus estimate company guidance solid contribution hologic molecular diagnostic breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline international revenue be cer banking strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer first quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive increase market share utilization fully automate panther system continue solid uptake aptima woman health product cytology perinatal revenue also show rise cer revenue breast health segment inched cer revenue unite state slip report quarter change product mix be partially offset increase service new product revenue international revenue however climb year year cer revenue gyn surgical business be cer medical aesthetic business quarter report revenue determine total revenue revenue skeletal health accounting rest decrease cer operational updatein fiscal first quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit first quarter fiscal cash cash equivalent report end first quarter fiscal total long term debt be end report quarter compare year quarter company generate operate cash flow compare year cash flow guidancehologic have update fiscal financial guidance company currently expect adjust revenue grow range compare previously provide range cer current zack consensus estimate be guide range adjust ep be expect grow previously state range current zack consensus estimate adjust ep be peg guide range second quarter fiscal hologic expect adjust revenue represent annualize growth cer current zack consensus estimate revenue be peg project range adjust ep be project cent reflect annualize growth current zack consensus estimate second quarter adjust ep be peg cent company guidance have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter compare lower hologic inc price consensus hologic inc price consensus hologic inc quotevgm scoresat time holx have subpar growth score however momentum be do lot better charting somewhat similar path stock be allocate grade value side putt top investment strategy overall stock have aggregte vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum investor value investor outlookestimate have be broadly trend upward stock magnitude revision look promising notably holx have zack rank hold expect line return stock next few month
374,HOLX,hologic inc holx free report have moved step forward core breast health business new product add kitty company have announce have commercially launch brevera breast biopsy system corlumina imaging technology unite state company real time breast biopsy verification system enhance patient experience streamline entire biopsy process notably brevera system claim be world first only breast biopsy solution combine tissue acquisition real time imaging sample verification advanced post biopsy handle integrate system design breast biopsy technical method increase biopsy accuracy real time imaging thus help perform fast efficient procedure cost save manner hologic new advancement be major breakthrough radiologist be hitherto conduct stereotactic breast biopsy procedure diagnose breast cancer conventional practice be time consume well uncomfortable patient brevera system image tissue sample be obtain right procedure room few second only good news be highly sophisticated technology potentially save minute patient cut procedure time almost hologic also claim brevera system proprietary corlumina imaging technology help improve multiple department health system also feature pacs integration advanced image sharing transfer patient record significantly breast health segment hologic have reshape strategy continuous innovation leadership position mammography latest brevera routine be affirm prone biopsy system management be hopeful brevera begin boost growth add more meaningful contribution also june hologic have announce fda labele genius mammography exam better standard mammography routine breast cancer screening woman dense breast hologic be pretty confident strong adoption brevera breast biopsy system market look forward company consistent effort flourish field woman health regard be important mention immense growth opportunity healthcare market hold present datum provide market market breast imaging market be expect reach cagr however more search reveal global breast biopsy market advance cagr period research market datum publish business wire last month company share price have underperform broader industry stock have lose compare broader industry fall zack rank key pickshologic carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
375,HOLX,bid enhance breast health portfolio hologic inc holx free report recently announce worldwide collaboration deal royal philips phg free report lead health technology company global partnership agreement provide integrate imaging solution woman health notably financial detail multus year exclusive global partnership agreement have not be disclose agreement have be sign offer integrate solution care professional solution include diagnostic imaging modality advanced informatic service screening diagnosis treatment woman world deal couple hologic innovative mammography technology philips lead portfolio ultrasound mri ct ray system advanced informatic broad range service be anticipate boost breast skeletal health solution segment former partnership hologic philips work project previously not be undertake company press release part multus modality deal hospital health system philips now be able offer select product hologic breast health portfolio include latter new dimension mammography system breast health unit focussolid growthwe be upbeat hologic consistent effort gain traction breast health business have contribute company overall top line growth first quarter fiscal segment have record growth constant currency quarter company unique direct consumer initiative segment have provide competitive edge niche space recent development segmentin november company announce development distribution agreement clarius mobile health portable ultrasound scanner system company also announce receipt clearance fda quantra breast density assessment software later month notably software be used hologic mammography system segment company have redesign strategy continue innovation leadership position mammography also november company announce plan make mammography system available dutch breast cancer screening program collaboration tromp medical hologic distributor netherlands line start hologic latest dimension mammography system be install mobile stationary screening facility netherlands september hologic announce commercial launch dimension mammography system europe notably conjunction enhance image quality radiologist system provide improve technologist moreover aim provide more comfortable mammography experience low dose option company be optimistic recent addition suite breast cancer screening diagnostic interventional solution breast health business market trend buoy optimismper report dpi research medium breast cancer screening market unite state be expect reach value roughly also report gbi research global breast cancer treatment market reach value cagr thus company clearly have solid prospect market share price performanceover past month hologic have decline underperform industry gain however company estimate revision trend current year have be encourage past couple month analyst moved north versus movement south earning estimate have be raise share same time frame zack rank key pickshologic carry zack rank buy couple top rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
376,HOLX,hologic inc holx free report have be healthy growth trajectory late company progress domestic international market strong pipeline product well huge future prospect gyn surgical molecular diagnostic segment make attractive pick moment therefore zack rank buy stock boast solid prospect drive share higher term stock have market cap company expect growth rate be company have average positive earning surprise last quarters also have long term expect earning growth rate company estimate revision trend current year have be positive past couple month analyst moved north southbound estimate witness earning estimate have be raise share same time frame let find recent favorable trend be sustainable hologic first quarter fiscal performance be quite promising primarily strength molecular diagnostic headquarter bedford company global growth be drive increase market share utilization fully automate panther system continue solid uptake aptima woman health product notably aptima woman health assay be dominant testing lab detect chlamydium gonorrhea hpv human papillomavirus trichomona hologic inc price hologic inc price hologic inc quote however performance gyn surgical space be disappointing report quarter majorly due external factor moreover extra selling day prior year period left significantly adverse effect year year comparison situation also grow tougher quarter review company register windfall gain year quarter recall competitive product accordingly hologic have underperform broader industry last month stock have lose broader industry rise nonetheless hologic gyn surgical business show huge future prospect fact be upbeat recent commercial launch myosure manual device unite state addition same myosure product portfolio consist myosure myosure reach myosure xl myosure lite device myosure continue show solid growth company pursue string developmental strategy surgical space notably hologic have appoint new leadership month team have upgrade sale talent structure growth boost incentive other key pickssome other top rank stock broader medical space be athenahealth inc athn free report express script hold company esrx free report bioverativ inc sporting zack rank strong buy see complete list today zack rank stock here athenahealth have expect long term growth rate past month stock have gain express script have project long term growth rate past month stock have return bioverativ have expect long term growth rate past month stock have return zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
377,HOLX,feb issue update research report hologic inc holx free report stock carry zack rank buy hologic post better expect result first quarter fiscal primarily strength molecular diagnostic fiscal first quarter sale increase cer company global growth be drive increase market share utilization fully automate panther system continue solid uptake aptima woman health product notably aptima woman health assay be dominant testing lab detect chlamydium gonorrhea hpv human papillomavirus trichomona performance gyn surgical space be disappointing report quarter due external factor majorly moreover extra selling day prior year period left significantly adverse effect year year comparison situation grow tougher quarter review company register windfall gain year quarter recall competitive product nonetheless hologic have huge future prospect business be upbeat recent commercial launch myosure manual device unite state addition myosure manual myosure product portfolio consist myosure myosure reach myosure xl myosure lite device myosure continue show solid growth company pursue string developmental strategy surgical space notably hologic appoint new leadership month team upgrading sale talent structure growth boost incentive flip side blood screening divestiture continue impede growth foreign currency headwind competitive landscape also persistently challenge company past month hologic have be trading industry stock have decline industry gain other key pickssome other top rank stock broader medical space be centene cnc free report athenahealth athn free report bioverativ sporting zack rank strong buy see complete list today zack rank stock here centene have impressive project long term growth rate stock have return last month athenahealth have expect long term growth rate stock have gain last month bioverativ have expect long term growth rate stock have soar last month wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
378,HOLX,hologic inc holx free report report first quarter fiscal adjust earning share ep cent year year moreover adjust ep beat zack consensus estimate surpass company guidance cent report basis company record ep compare cent first quarter fiscal notably report figure include time tax provision net benefit courtesy tax reform revenue detailrevenue gross quarter year year constant exchange rate cer top line also exceed zack consensus estimate company guidance solid contribution hologic molecular diagnostic breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline international revenue be cer banking strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesegment detailrevenue diagnostic segment total revenue decline year year cer first quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive increase market share utilization fully automate panther system continue solid uptake aptima woman health product cytology perinatal revenue also show rise cer revenue breast health segment inched cer revenue unite state slip report quarter change product mix be partially offset increase service new product revenue international revenue however climb year year cer revenue gyn surgical business be cer medical aesthetic business quarter report revenue determine total revenue revenue skeletal health accounting rest decrease cer operational updatein fiscal first quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit first quarter fiscal cash cash equivalent report end first quarter fiscal total long term debt be end report quarter compare year quarter company generate operate cash flow compare year cash flow guidancehologic have update fiscal financial guidance company currently expect adjust revenue grow range compare previously provide range cer current zack consensus estimate be guide range adjust ep be expect grow previously state range current zack consensus estimate adjust ep be peg guide range second quarter fiscal hologic expect adjust revenue represent annualize growth cer current zack consensus estimate revenue be peg project range adjust ep be project cent reflect annualize growth current zack consensus estimate second quarter adjust ep be peg cent company guidance takehologic post better expect result first quarter fiscal term earning revenue growth geographical region buoy optimism however be disappoint decline revenue company diagnostic segment blood screening divestiture be also likely impede growth momentum company zack rank key pickshologic carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
379,HOLX,be thick fourth quarter earning season member have report number current earning season have see average proportion positive surprise favorable revision trend present upcoming quarter strong revenue momentum latest earning preview total earning company have report so far be year year higher revenue total beat earning surpass revenue estimate member line release quarterly result week be decidedly bullish equity market be gradually demonstrate sequential improvement medtech earning so farmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be evident result medtech heavyweight laboratory corporation america holding lh free report labcorp becton dickinson company bdx free report company end fourth quarter solid note earning beating zack consensus estimate upbeat fy guidance also instill confidence regard labcorp adjust ep guidance be range further becton dickinson company expect adjust earning share band previous fourth quarter expect earning growth rate sector be revenue growth cah holx see stronger earning let take look major medtech stock cardinal health cah free report hologic inc holx free report slate release quarterly report feb cardinal health be schedule release result market open notably zack consensus estimate second quarter fiscal revenue be peg year year diverse product portfolio cardinal health be largest distributor pharmaceutical medical supply however zack consensus estimate second quarter earning be peg year year company face risk lose considerable business case loss major customer severely impair bottom line fact cardinal health announce loss large mail order customer prime therapeutic dent revenue company specialty pharmaceutical distribution segment last quarter cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quotemoreover quantitative model do not conclusively show beat cardinal health be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate cardinal health have zack rank earning esp uncover best stock buy sell re report earning esp filter read more store cardinal health earning hologic be set report first quarter fiscal result market close notably zack consensus estimate earning be cent year year basis diagnostic segment be expect record revenue year quarter also zack consensus estimate show decline year year be blame estimate loss divest blood screening franchise also company have be see weak sale cytology perinatal product late bright side zack consensus estimate first quarter revenue be peg year year company be expect see stellar performance molecular diagnostic major sub segment diagnostic unite state company be expect gain expand market utilization fully automate panther system hologic inc price ep surprise hologic inc price ep surprise hologic inc quoteour quantitative model indicate earning beat hologic quarter have favorable combination earning esp zack rank see complete list today zack rank stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
380,HOLX,investor be always look stock be poise beat earning season hologic inc holx free report be such company firm have earning come pretty soon event be shape quite nicely report be hologic be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface holx report analyst have very recently bump estimate holx give stock zack earning esp head earning season hologic inc price ep surprise hologic inc price ep surprise hologic inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give holx have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead hologic beat be card upcoming report more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
381,HOLX,hologic inc holx free report be slate report second quarter fiscal financial result close bell last quarter company deliver positive surprise notably hologic earning surpass zack consensus estimate past quarters average beat let see thing be shape prior announcement key catalystwithin diagnostic hologic once again expect stellar performance banking molecular diagnostic unite state company be likely gain increase market share well utilization fully automate panther system market expansion conform testing guideline global growth molecular diagnostic be attribute panther system hologic fully automate molecular diagnostic instrument also owing frequent utilization aptima woman health assay notably aptima assay have gain huge customer base testing chlamydium gonorrhea hpv human papillomavirus trichomona be also hopeful hologic expand market sexually transmit disease testing hologic inc price ep surprise hologic inc price ep surprise hologic inc quote further be upbeat diagnostic business earn regulatory clearance several new product unite state last quarters include first respiratory assay new fusion platform viral load test hiv human virus hepatitis hepatitis steady pace domestic assay innovation strengthen company position consolidate molecular testing panther system january company again announce pma approval aptima hbv quant assay quantitation hepatitis viral load fully automate panther system development be anticipate contribute significantly company topline be report quarter zack consensus estimate molecular diagnostic revenue reflect increase year quarter other few factor likely influence hologic result fiscal second quarter be follow hologic be optimistic sustain solid earning trend courtesy gain breast health segment sale same have improve basis establish clinical superiority segmental product last quarters company have witness consistent rise market share breast health back direct consumer initiativesand insurance coverage additionally company adoption new mammography system dimension performance encourage new product have already start leverage company genius brand also lure customer upgrade exist system company be build broader portfolio breast health product service core genius system so play instrumental role breast health continuum care noteworthy regard be recent pma approval fda clarity hd high resolution imaging intelligent imaging technology product be now available dimension breast tomosynthesis system zack consensus estimate second quarter fiscal remain ahead prior year tally flip side hologic confront challenge related unfavorable foreign currency movement past few quarters escalate operate expense intense competition particularly tomosynthesis market continue raise concern model suggestsper proven zack model company solid zack rank strong buy buy hold have higher chance beating estimate also have positive earning esp hologic have zack rank increase predictive power esp earning esp raise confidence positive surprise together combination suggest company be likely beat earning quarter uncover best stock buy sell re report earning esp filter conversely caution sell rate stock go earning announcement especially company be see negative estimate revision other stock worth lookhere be few other medical stock worth consider right combination element also surpass estimate time baxter international inc bax free report have earning esp zack rank laboratory corporation america holding lh free report have earning esp zack rank stryker corporation syk free report have earning esp be zack rank player see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
382,HOLX,pacific bioscience california inc pacb free report first quarter result expect release apr be assume show steady growth product revenue wing core business majorly drive growth decline revenue other segment mar company prospect first quarter last report quarter company report loss cent share year year miss zack consensus estimate penny revenue come beating zack consensus estimate year year basis notably first quarter zack consensus estimate be peg loss cent share reflect year year growth other hand zack consensus estimate revenue be pin indicate decline pacific bioscience report average negative earning surprise trail quarters let delve deeper number pacific bioscience california inc price ep surprise pacific bioscience california inc price ep surprise pacific bioscience california inc quoteproduct revenue focuspacific bioscience flagship platform sequel system have be fortify company footprint worldwide fiscal product revenue account whopping company net revenue fourth quarter fiscal segment post revenue worth year year be encourage note current quarter zack consensus estimate segment revenue be fix year year basis consumable revenue fourth quarter be year year basis mark metric eighth consecutive quarter growth continue consumable sale momentum upside be drive increase utilization company grow install base sequel system also know pacbio sequel system however instrument revenue dip year year basis other factor playpacbio sequel system drife growthper management sequel generate revenue grow more fold fourth quarter represent whopping fourth quarter revenue additionally bgi china order sequel system make primary growth driver pacific bioscience past year number study have be used plan use pacbio whole genome sequence goal increase cure rate genetic disease study include stanford university school medicine european solve rd consortium perform individual rare disease study novogene have announce plan sequence chinese genome platform have also witness series development lately flagship pacbio sequel be currently be used alabama base hudsonalpha institute biotechnology support goal dramatically increase diagnostic success rate challenge pediatric clinical case moreover beij base annoroad gene technology have recently place purchase order pacbio sequel system be expect increase annoroad large scale genomic service capability various field view first quarter revenue be expect be slightly lower report count fourth quarter fiscal due seasonality banking better expect fourth quarter show pacific bioscience expect revenue grow year figure translate approximately total revenue shrink service revenue marginsin last report quarter revenue service other segment fall year year basis almost full year fiscal revenue segment deteriorate compare full year zack consensus estimate segment revenue first quarter be fix year year other hand gross margin quarter be basis point year year company incur operate loss wider loss year quarter here be quantitative model predict pacific bioscience carry zack rank buy do not have positive earning esp need increase odd earning beat zack esp earning esp pacific bioscience be uncover best stock buy sell re report earning esp filter zack rank pacifc bioscience carry zack rank increase predictive power esp however also need positive esp be confident earning beat stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter stryker corp syk free report have earning esp zack rank see complete list today zack rank strong buy stock here hologic inc holx free report have earning esp zack rank hold edward lifescience ew free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
383,HOLX,perkinelmer inc pki free report first quarter result expect release apr market close be likely show steady growth core diagnostic business prove be major driver decline revenue other segment mar overall result fourth quarter fiscal company report adjust earning cent share beating zack consensus estimate cent meanwhile revenue be approximately beat zack consensus estimate revenue also surpass year quarter notably first quarter zack consensus estimate earning be peg cent reflect year year growth same revenue be pin indicate growth perkinelmer deliver average positive earning surprise trail quarters perkinelmer inc price ep surprise perkinelmer inc price ep surprise perkinelmer inc quotelet dig deeper diagnostic revenue focusdiagnostic revenue account total revenue last quarter revenue segment rise year also reflect improvement organically segment have be fortify company market position term exclusiveness service respective market diagnostic market company offer product be used detect genetic disorder perkinelmer also provide digital ray flat panel detector infectious disease testing solution diagnostic portfolio first quarter result be likely indicate strong growth diagnostic revenue last report quarter operate profit margin segment percentage revenue be basis point bps year year be also encourage note zack consensus estimate diagnostic segment be sequentially other factor playeuroimmun buyout divestment medical imaging business acquisition euroimmun medical laboratory diagnostic ag have be major driver segment perkinelmer announce completion euroimmun buyout approximately cash december euroimmun be autoimmune testing company emerge player infectious disease allergy testing space management euroimmun buyout have expand perkinelmer capability help gain considerable traction have lead increase diagnostic employee more strengthen company platform company be optimistic increase spending be likely account product revenue fourth quarter euroimmun contribute revenue approximately represent growth be also likely add bps perkinelmer organic growth discovery analytical solution da revenue da totale fourth quarter year quarter perkinelmer have be focuse finalize organizational change associate life science business da lately company have collaborate helix develop commercialize sequence base test help consumer take proactive health management decision however zack consensus estimate revenue be sequentially guidance company issue adjust earning guidance adjust earning be expect share further expect report revenue range include approximately foreign exchange tailwind euroimmun perkinelmer project organic revenue growth thus perkinelmer be confident improve growth trajectory first quarter quantitative model show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp perkinelmer be uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
384,HOLX,athenahealth inc athn free report be schedule report first quarter result apr market close company strong product portfolio solid network expansion strategy unique business model be key tailwind moment last quarter athenahealth post adjust earning share beat zack consensus estimate cent further earning increase whopping year year basis company post revenue beating zack consensus estimate revenue increase year year current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg cent indicate increase year year athenahealth inc price ep surprise athenahealth inc price ep surprise athenahealth inc quotewe expect athenahealth witness steady growth business service sale major revenue component be project drive first quarter earning expect improvement implementation other segment also help company generate impressive result consider question linger investor mind be athenahealth be able deliver positive earning surprise be report quarter let delve other factor be likely impact company first quarter result business service focusbusiness service contribute net revenue last quarter upcoming quarterly result zack consensus estimate business service be peg reflect rise year year application athenaclinical athenaclinical streamline athenainsight athenaone athenacollector hospital health system brand promise unbreak healthcare come athenahealth business service segment segment have be fortify company market position term exclusiveness service respective market athenahealth unique business model make strong niche provider revenue cycle management rcm service small physician practice meanwhile research report market market global revenue cycle management market be project reach cagr upcoming result be likely indicate strong growth business service unit other factor other contribute net revenue last quarter zack consensus estimate implementation other be peg reflect rise year year segment include electronic health record ehr electronic medical record implementation late athenahealth have be hog limelight cloud base big datum network athenanet recently company launch machine learn model automate faxe development implementation other be likely drive athenahealth be likely be reflect first quarter result strong product portfolio comprise wide array product include electronic health record revenue cycle management medical bill patient engagement care coordination population health management epocrate end fourth quarter athenahealth launch first machine learn model automate faxe company pilot service authorization management have be plan expand company client base athenainsight online news hub report healthcare activity trend healthcare provider identify patient have also be major contributor athenahealth rapidly expand patient record sharing capability commonwell carequality upcoming quarterly result reflect benefit company strong product portfolio aggressive rivalryon flipside athenahealth ehr solution face significant competition like allscript healthcare solution other competitor such cerner offer long standing seamless product integrate inpatient ambulatory care system dampen company prospect reflect first quarter result model predictsour quantitative model do not conclusively predict earning beat athenahealth quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated zack esp earning esp athenahealth be uncover best stock buy sell re report earning esp filter zack rank athenahealth carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter edward lifescience corporation ew free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank teleflex incorporate tfx free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
385,HOLX,only handful player have release number so far earning season expect first quarter see strong revenue reflect solid upward trend estimate revision meanwhile back back event quarter have rattle global economy first be china trade war chaos then come tech backlash stem facebook fb datum fiasco finally chemical attack syrium pave way fresh trouble america russia furthermore apprehension related further rate hike fed continue do round be medical device safe haven be say stock market run sentiment unforeseen event particular sector have ripple effect other go notion medical device sector broader medical universe have proven be refuge investor shrug ongoing tension sector have return year date significantly higher return be medical device company have be ride high innovation increase consolidation focus emerge market tax abolition fact latest earning preview give encourage picture broader medical space expect register year year earning growth revenue growth so rather be interesting see medical device company be place ahead report cycle be major factor shape release growth driversgo cision report unite state be largest medical device market world rake more revenue have be very profitable investment space late consider agee population change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment increase business investment medical device sector appear be pink health here be latest headline space taxe abolish bipartisan year suspension medical device tax impose excise tax medtech manufacturer have be temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer instilling investor optimism ratification tax repeal amendment have encourage massive investment sector digital revolution take medtech latest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space have be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity evidently company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late buyout rushlately health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer base moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script esrx cigna follow just month drug chain pharmacy giant cvs health corp cvs announcement plan acquire nation third largest health insurer aetna be important becton dickinson company bdx takeover bard be also worth mention zack methodology rescuegiven existence number player medical device industry find right stock have potential beat earning banking factor quite intimidate task proprietary zack methodology however make fairly simple narrow choice focuse specifically medical instrument medical product stock specialize chunk medical device subcategory sport desirable combination positive earning esp favorable zack rank strong buy buy hold earning esp be proprietary methodology determine stock have best chance surprise next earning announcement provide percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high go criterion hereby present stock be poise beat estimate quarter picksedward lifescience corporation ew free report headquarter irvine edward lifescience deal product technology aim treat advanced cardiovascular disease especially structural heart disease critically ill patient company strong pipeline product solid performance deliver tavr market bolster confidence stock edward lifescience higher operate expense have make investor apprehensive be respite fund be used adopt advanced initiative drive overall sale edward lifescience report first quarter result apr market close believe company be set beat zack consensus estimate have zack rank earning esp hologic inc holx free report headquarter bedford hologic develop manufacture supply diagnostic medical imaging system surgical product cater healthcare need woman company be focuse mammography system breast examination osteoporosis assessment company release result second quarter fiscal market close hologic zack rank earning esp raise possibility beat quarter meanwhile see complete list today zack rank stock here stryker corporation syk free report headquarter kalamazoo mi stryker be world largest medical device company operate orthopedic market mako be stryker robotic arm assist surgery platform provide predictable surgical experience perform joint replacement surgery recently stryker launch robotic arm assist total knee arthroplasty application use mako system notably be first only robotic technology be used total knee hip partial knee replacement procedure notably mako total knee utilize stryker robotic platform triathlon total knee system guide ct base modele bone anatomy system also allow intra operative plan assist bone resection procedure stryker report first quarter result apr market close believe stryker be poise trump zack consensus estimate have encourage combination zack rank earning esp teleflex incorporate tfx free report headquarter wayne pa teleflex develop manufacture supply single use medical device common diagnostic therapeutic procedure critical care surgical application worldwide company strong focus high flow nasal cannula therapy hfnct be likely lend competitive edge niche space solid growth preload microbial thrombogenic vps piccs platform be likely strengthen vascular platform surgical segment new product efx ae fortify company foothold finally company flagship lma unique product strengthen anasthesia product line company be expect report first quarter result expect earning beat stock have zack rank earning esp hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
